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General Summary 
On activation cells shed vesicles from their surface by the process of ectocytosis. These micro-
vesicles or Ectosomes express phosphatidyl-serine (PS) on their surface, which can elicit a 
range of biological effects from immune-suppression to the activation of the clotting and 
complement pathways. While the full consequence of this phenomena is still subject of intensive 
research, it is clear that microvesicles, despite their size, can profoundly impact the immune 
system. 
 The aim of this thesis was to study clinically relevant scenarios where micro-vesicle release 
alters the course of inflammation. The conditions studied were: 
1. The release of neutrophil microvesicles (PMN-Ecto) and spontaneous resolution of Gout.
Gout is an inflammatory arthritis caused by mono-sodium urate crystals (MSU) 
precipitating in joints. When attempting to clear MSU, resident macrophages activate 
their inflammasome complex and release large amounts of highly inflammatory cytokine 
IL-1β. One of the intriguing features of gout is that acute attacks resolve spontaneously 
and leave minimal residual damage to the joint. The mechanism driving the resolution of 
gout is still poorly understood. We hypothesized that the early release of PMN-Ecto 
during acute gout contains the inflammatory response to MSU. 
In a murine peritonitis model of gout we found that the release of IL-1β following 
stimulation with MSU relied on the generation of C5a by MSU itself. Neutrophils 
infiltrating the peritoneum in response to C5a released phosphatidylserine (PS)-positive 
ectosomes early on in the course of inflammation. Treatment of the peritoneum with 
these PMN-Ecto in turn resulted in suppression of IL-1β release and translated in a 
decrease of PMN influx. Ectosome-mediated suppression could be reproduced using 
PS-expressing liposomes and required the presence of the PS-receptor MerTK. Finally, 
PMN-Ecto from joint aspirates of patients with gouty arthritis had similar anti-
inflammatory properties. Ectosome-mediated control of inflammasome-driven 
inflammation is a compelling concept of autoregulation initiated early on during PMN 
activation in gout. 
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2. Platelet microvesicles (PLT-Ecto) and sub-clinical disseminated intravascular 
coagulopathy (DIC) during anti-thymoglobulin therapy  (ATG). 
 
Anti-Thymo-Globulins (ATG) are T-cell depleting antibodies used for hematopoietic stem 
cell (HSCT) and kidney (NTX) transplant patients as an immuno-suppressant to 
prevention graft vs. host disease (GvHD). Although designed to target T-cell, ATG 
recognizes a wide range of epitopes, including those present on platelets. Consequently 
the rapid infusion of ATG frequently cause side effects that are associated with the overt 
activation of the clotting system called DIC. The mechanism relating ATG therapy to DIC 
remains unclear. We hypothesized that ATG induces DIC by the release of pro-
coagulant PLT-Ecto.   
 
We could demonstrate that ATG induces platelet activation, degranulation and release of 
PLT-Ecto. The shedding of PLT-Ecto required the presence of complement and could be 
inhibited by an anti-C5 blocking antibody. PLT-Ecto exhibited high pro-thrombinase 
activity. The blocking of C5 during ATG treatment of platelets therefore indirectly 
inhibited thrombin generation. In HSCT and NTx patients, ATG treatment resulted in 
elevated levels of d-dimer and thrombin-anti-thrombin complexes indicating heightened 
state of clotting. Furthermore, we could confirm the presence of PLT-Ecto in patients 
plasma and ATG dose dependent complement fragment deposition on PLT-Ecto.  
In conclusion, ATG induced complement dependent release of pro-coagulant PLT-Ecto 
and the use of anti-C5 antibody may prove to be beneficial in preventing thrombotic 
complications during ATG therapy. 
 
3. Red Blood cell microvesicles (RBC-Ecto) and transfusion related complication. 
 
Transfusion of RBC is known to exacerbate systemic inflammation and increase 
morbidity and mortality of critically ill patients. The adverse effect of RBC transfusions 
has been attributed to changes that occur during extended periods of RBC storage. The 
ageing process of RBC is accompanied by the shedding of RBC-Ecto, which accumulate 
in storage and are transfused along with RBC. We hypothesized that RBC-Ecto derived 
from aged RBCs amplify systemic inflammation and contribute to some of the 
deleterious effects of aged blood transfusions. 
7
We established a murine transfusion model using RBC-Ecto purified from aged 
erythrocytes. While the injection of RBC-Ecto into healthy mice had no effect, transfusion 
of RBC-Ecto amplified systemic inflammation in endotoxemic mice. These effects were 
mediated by a thrombin depenedent activation of C5 complement factor on the surface 
of RBC-Ecto. Consequently, the treatment of mice with a thrombin anticoagulant prior to 
transfusion alleviated the proinflammatory effects of RBC-Ecto. The inhibition of 
thrombin in vivo lead to suppresion of systemic C5a generation, inflammatory cytokine 
release and subsequently lung neutrophil sequestration. 
In conclusion, we could identify RBC-Ecto as potential mediators of transfusion related 
morbidity. RBC-Ecto mediated their effects by sequentially activating the coagulation 
and complement system, which then aggrevated systemic inflammation. 
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General introduction 
 
Microvesicles, Ectosomes and Exosomes 
 
Micro-vesicle (MV) is a general term used to describe sub-micron sized vesicles released by 
cells upon stimulation (1, 2). Based on their mechanism of release, MV’s can be divided into two 
distinct subsets,  Ecto-somes and Exo-somes. Ectosomes (Ecto) are vesicles shed directly from 
the surface of the cell. During ecto-cytosis small cytoplasmic protrusions bud outward from the 
plasma membrane and detach by fission of their stalk (Figure 1). Exosomes, unlike Ectosomes, 
are formed by the intra-cellular inward budding of the late endosomal compartment and 
released by the exocytosis of these multi-vesicular bodies (MVB) (Figure 1). The different 
mechanisms by which MVs are formed reflect in the way they convey their biological message. 
While Ectosome rely on direct cell-MV contact, Exosome alter cell behavior by delivering their 
cargo molecules (miRNA) to target cells (2, 3). The biological effect of MVs is therefore defined 
either by what they express on their surface (Ectosomes) or by what they contain and transfer to 
cells (Exosomes). MV release represents a new form of inter-cellular communication. Neutrophil 
(PMN), erythrocyte (RBC) and platelet (PLT) Ectosomes are the subject of this thesis. 
 
Vesicles shed by ectocytosis maintain their right-side out orientation of their plasma membrane, 
but lose the asymmetrical distribution of membrane phospholipids characteristic for resting cells. 
The absence of lipid asymmetry and expression of phosphatidyl-serine (PS) is one of the 
defining features of ectosomes and is closely related to both their biological effect and 
mechanism of release (1).  
Although resting cells release ectosomes constitutively, the rate of the process increases 
dramatically upon stimulation (4-6). Sub-lytic complement attack, C5a, fMLP, phorbol ester 
activation of protein kinase C and Ca2+ ionophores are known to induce strong shedding 
responses (7-11). The converging mechanism of these triggers, is the influx or release of Ca2+ 
accompanying cell stimulation. Ca2+ influx drives the translocation of PS, a phospholipid from 
the  inner side of the plasma membrane, to the outer leaflet (12). PS exposure is followed by 
MV release allowed by cytoskeleton degeneration by Ca2+ dependent proteolysis. Membrane 
remodeling and MP shedding seems to be a fundamental process probably shared by virtually 
all cell types. Ectosomes released by activated PMN, RBC and PLT consequently stain positive 
for Annexin V (AnV), which binds PS. Microvesicles, unlike their parent cells, continue to stably 
express PS since they lack the energy necessary to restore asymmetric lipid distribution. 
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Neutrophil ectosomes (PMN-Ecto) were initially described as a means by which neutrophils 
confer resistance to a sub-lytic complement attack. During complement activation, neutrophils 
expel membrane attack complexes (MAC, C5b-9) by ectocytosis of vesicles (7). The shedding 
of vesicles has later been confirmed to be a generalized phenomena of neutrophil activation. 
C5a and fMLP induce one of the strongest shedding responses (9). 
PMN-Ecto are heterogeneous, predominantly spherical vesicles that range 100-500nm in size. 
During ectocytosis PMN-Ecto acquire a select panel of proteins and lipids, from their parent 
cells (8, 9). This implied early on that ectocytosis is not a random event, but involves specific 
sorting mechanisms. PMN-Ecto express CD66b, CR1, selectins, integrins (CD11a,CD11b ), 
complement regulators (CD46, CD55, CD59), HLA-1 and FcγRIII, but not CD14, FcγRII and 
CD87. The selective inclusion and exclusion of proteins is not specific to transmembrane or 
GPI-linked proteins. In addition, PMN-Ecto actively recruit neutrophil enzymes from azurophilic 
(MPO, PR3 and NE) and specific (MMP-9) granules to their surface. These enzymes retain their 
catalytic activity. As all ectosomes, PMN-Ecto express PS on their surface and consequently 
stain positive for Annexin V (AnV), Annexin A1 (AnA1), C1q and Gas6 (9, 13). 
PMN-Ecto are anti-inflammatory. PMN-Ecto generated by C5a stimulated PMN attenuate the 
cytokine response (TNFα, IL-6,-8,-12) of human monocyte derived macrophages (HMDM) to 
TLR ligands (LPS, ZymA) in vitro (14). They achieve this by engaging the MerTK-PI3K/Akt 
pathway, which inhibits NFκB trans-activation upon TLR stimulation (15). The binding  of PMN-
Ecto to cells is sufficient to mediate suppression and PS containing liposomes can reproduce 
their effect. In addition to PS, PMN-Ecto foster these anti-inflammatory effects by inducing the 
release of TGFβ in target cells (16).  
 
Erythrocyte ectosomes (RBC-Ecto) were first described to be released by erythrocyte under 
complement attack (11). As with PMN-Ecto, RBC-Ecto shedding allows erythrocytes to survive 
sub-lytic complement activation by removal of the MAC (C5b-9 complex). RBC-Ecto can also be 
released in a much slower and gradual process of erythrocyte senescence (17-19). The 
progressive decline in membrane fluidity, osmotic stability, lipid and protein oxidation is 
accompanied by the release of RBC-Ecto. This is particularly apparent during extended storage 
of erythrocyte transfusion units (storage lesion) where RBC-Ecto accumulate over time.  
RBC-Ecto are homogenous spherical vesicles 50-200nm in size that express glycophorin A, 
complement regulators (CR1, CD55, CD59) and contain hemoglobin (19). RBC-Ecto are PS 
positive and bind both C1q and Annexin V (AnV). RBC-Ecto generated either from aged RBC or 
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induced by a Ca2+ ionophores suppress HMDM pro-inflammatory cytokine response to TLR 
ligands the same way as PMN-Ecto with exception of their inability to trigger TGFβ release. 
 
Platelet ectosomes (PLT-Ecto) are released by activated platelets and constitute the dominant 
population of circulating MVs. Circulating PLT-Ecto are shed by activated platelets and support 
hemostasis by generating thrombin on their negatively charged PS expressing surface (20-22). 
As with all Ecto, PLT-Ecto can be induced by sub-lytic complement attack (10) and their release 
is triggered by the Ca2+ influx caused by C5b-9 deposition (23).  
PLT-Ecto are 100-500nm in size and express platelet specific markers (CD36, CD41, CD47, 
CD61), complement inhibitors (CD55, CD59) and PS (24). In addition to membrane proteins, 
PLT-Ecto bind C1q and factor H from plasma. PLT-Ecto are known to down-modulate immune 
responses of HMDM in vitro.  
 
Ectosomes, The Inflammasome and Gout 
 
Gout is a type of inflammatory arthritis triggered by the precipitation of MSU crystals in joints 
(25). MSU crystals are a potent activator of the NLRP3 inflammasome complex, a molecular 
platform that is responsible for IL-1β secretion (26).  IL-1β is a crucial mediator that drives gouty 
inflammation (25).  
 
The NLRP3 inflammasome is primarily designed to integrate bacterial (pathogen associated 
molecular patterns, PAMP) and danger signals (danger associated molecular patterns, DAMP) 
(25, 27, 28) (Figure 2). The purpose behind this design is to ensure the inflammasome is active 
only in a circumstances when pathogenic microbes are causing tissue damage. This allows the 
immune system to mount a coordinated response to infection and injury, while remaining 
unresponsive to ‘harmless’ non-self. This ‘danger’ hypothesis has been first articulated by 
Matzinger who defined innate immunity as a danger sentinel (29-31). The dual requirement for 
concomitant PAMP and DAMP stimulation is inbuilt in innate cells, which express low levels of 
critical components of the inflammasome (pro-IL-1β, NLRP3), which in the absence of PAMP 
limits their activation potential (32-34). MSU and MSU crystals in this context represent danger 
signals (35). Uric acid is an end product of purine metabolism and high extracellular 
concentrations of MSU signify high cell turnover and cell damage. The precipitation of MSU 
crystals in joints has various triggers including infection and joint trauma. Resident 
macrophages attempt to clear these crystals, but ultimately fail due to absence of uricase and 
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the crystal size that greatly exceeds their own. This is followed by some form of MSU danger 
recognition, inflammasome activation and IL-1β release.  
 
Specific recognition of MSU by the inflammasome is highly unlikely on account of the structural 
diversity of stimuli that have been shown to induce the NLRP3-dependent IL-1β secretion. It is 
hypothesized that all NLRP3 stimuli, including MSU, share the ability to trigger several 
intracellular events that result in NLRP3 activation (27) (Figure 3). Mitochondrial ROS is 
considered to be the most likely proximal signal for NLRP3 activation (36-38). The association 
of the inflammasome is purposeful, since mitochondria are sensitive to metabolic stress and 
ROS are evolutionary conserved  signals of danger. In fact, any mitochondrial stressor can 
induce the NLRP3 inflammasome assembly and recently thioredoxin-interacting protein (TXNIP) 
has been identified as the ROS sensitive regulator of the NLRP3 inflammasome (37). 
Phagocytosis is essential for particulate inflammasome activators (25, 39-41). Another model 
suggest that the uptake of particulates stimuli (AL, MSU) causes disruption of lysosomal 
membrane and the release of putative NLRP3-activating lysosomal contents (cathepsin B) into 
the cytosol causing cleavage of NLRP3 or its inhibitor (40, 42). Alternatively, ionic perturbations 
(K+ efflux, Na+ and H20 influx) due to endogenous ion channel (P2X7 channel for ATP) or pore-
forming bacterial toxins (nigericin) lead to intracellular hypo-kalemia and NLRP3 activation (43-
46). All three mechanisms are non-exclusive. Considering that: K+ efflux can lead to ROS 
production and ROS positively modulates K+ efflux (47, 48); K+ efflux is involved in the initiation 
of phagocytosis (49); ROS is a major promoter of lysosomal rupture and lysosomal 
permeabilization can induce ROS (50, 51), it is plausible to assume that some form of signal 
integration takes place and likely converges on the ROS-TXNIP-NLRP3 axis. The NLRP3 
inflammasome essentially detects a combination of loss of membrane stability (K+ efflux and 
lysosomal destabilization) and heightened metabolic stress (mitochondrial ROS).  
Inflammasome activation involves the assembly of the NLRP3 complex and caspase-1 
activation. NLRP3 consists of three components: the central nucleotide-binding and 
oligomerization domain (NACHT) flanked by the C-terminal leucine-rich repeats (LRRs) and N-
terminal pyrin domain (PYD). Activation signals are sensed by the LRR domain, which normally 
in an auto-repressed state obscuring access to the NACHT and PYD domain with the 
assistance of the SGT1 and HSP90 chaperones (26, 52). Upon sensing of intracellular danger 
signals, LRR auto-repression is relieved and the PYD and NACHT domain is exposed. This 
allows NLRP3 oligomerization by homotypic association of NACHT domains and the recruitment 
of the PYD-CARD adaptor ASC, which then recruits pro-caspsae-1 molecules. Pro-caspase-1 
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clustering leads to auto-activation to caspase-1 and subsequent cleavage of pro-IL-1β to IL-1β 
and its release.  
IL-1β has a wide range of biological effects (53). Systemically IL-1β acts as an endogenous 
pyrogen, induces an acute phase response, vasodilation and hypotension. Locally, IL-1β is a 
strong neutrophil and monocyte chemo-attractant, activates endothelial cells and facilitates 
neutrophil rolling and extravasation, enhances leakiness of capillaries and mediates sensation 
of pain. Consequently joints undergoing a gout attack present with swelling, redness, warmth 
and are extremely painful to touch. A gout attack typically escalates within an hour and can be 
even accompanied by systemic symptoms of fever and hypotension. 
 
In addition to IL-1β complement activation contributes to the inflammatory response to MSU 
crystals. High levels of active complement fragments are present in synovial fluids of patients 
with acute gout (54-56). The functional importance of complement has also been illustrated in 
animal models of acute gout, where depletion of, or deficiency in, complement components 
resulted in abrogation of MSU crystal-induced inflammation (57-59). Experiments with human 
serum in vitro have shown that MSU crystals activate complement by the classical and 
alternative pathway (56, 60-62). Although IgG can be found coating MSU crystals, the activation 
of C1q and the classical pathway was independent of IgG (60). In fact, the activation of many of 
the complement proteins appears to involve direct interactions with the negatively charged 
crystal surface, including assembly of a functional C5 convertase complex at the crystal surface 
resulting in the generation of active C5a (63). In vitro, C5a generated by MSU treated human 
sera, acted as a strong neutrophil chemo-attractant (63). C5a could be potentially responsible 
for amplifying neutrophil recruitment and licensing the inflammasome by C5aR mediated 
activation of NFκB (64-66). Concurrently, C5a induces a strong vesiculation response in 
neutrophils, which consequently release large amounts of PMN-Ecto (9, 14).  
 
The acute gouty inflammatory response is typically self-limiting within 7-10 days and leaves 
minimal residual damage to the joint (67). While there is no conclusive model on how gout 
resolution occurs, a range of potential mechanisms have been suggested and include: release 
of TGFβ,  clearance of apoptotic cells and desensitization of caspase-1.  
 
TGFβ is regarded as the prime mediator in the active resolution of gout. In clinical studies 
elevated levels of TGFβ have been reported in the synovial fluid of patients in the late stages of 
gout, suggesting that TGFβ may be involved in maintaining inflammatory quiescence during 
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asymptomatic periods (68-70). Furthermore, patients carrying functional polymorphisms of 
TGFβ had a higher incidence of a more aggressive forms of gout (tophaceous gout) (71). In 
vivo, extraneous administration of TGFβ attenuated neutrophil recruitment in response to MSU 
in a rat air-pouch model (72). In vitro studies have shown that as monocytes differentiate into 
macrophages they progressively lose their ability to release IL-1β and gain the capacity to 
release TGFβ in response to MSU (73). This implied that the resolution of gout is the 
consequence of monocyte differentiation. TGFβ in this model also suppressed the release of 
TNFα by LPS stimulated monocytes and inhibited endothelial cell activation in response to 
inflammatory cytokines (74). In monocytes TGFβ was shown to suppress IL-6 release by in 
response to IL-1β. Despite the indication of TGFβ involvement in gout, the mechanism of 
suppression remains unknown and cellular sources of endogenous TGFβ undefined. 
 
Another possible mechanism that may initiate resolution of gout is the clearance of apoptotic 
neutrophils. Neutrophils are the dominant cell population infiltrating the joint space during gout. 
They typically have a short life span and undergo apoptotic cell death in later phases of 
inflammation (75). Apoptotic neutrophils convey their anti-inflammatory signals by at least three 
mechanisms. PS expressed by apoptotic cells can activate various PS receptors including the 
family of TAM receptors (consisting of Tyro, Axl, Mer). The MerTK receptor is the most 
extensively studied and has been shown to suppress the inflammatory response of 
macrophages and DCs to TLR ligands (76). Furthermore, apoptotic cells are known to induce 
the synthesis and release of TGFβ (77, 78). The mechanisms of TGFβ release is not yet 
understood and may be associated with PS expression (78). Finally, the uptake of apoptotic 
cells alters the behavior of macrophages by inducing the so called alternative activation or M2 
phenotype (79, 80). Alternatively activated macrophages release anti-inflammatory cytokines 
(IL-10), pro-resolving lipid mediators (resolvins) and take part in connective tissue repair 
(Arginase) (81, 82).  
Lastly, the activation of the inflammasome complex can be restricted by two basic means that 
reflect the inherent/inbuilt limitations of the system. Low pro-IL-1β and NLRP3 expression in 
myeloid cells are the limiting factors of the inflammasome complex and therefore, prior to 
activation, the inflammasome requires licensing (32). Once primed, however, inflammasome 
activation is not self-sustaining and requires continuous pro-IL-β synthesis. The clearance or 
inactivation (C5a) of the priming agent may lead to a  decline in inflammasome activation as the 
synthesis of pro-IL-1β starts to lag behind the rapid pace of IL-1β release. Furthermore 
caspase-1 is a protease prone to inactivation by changes in redox potential (83). ROS 
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generated during mitochondrial stress were identified as one of the ‘danger’ signals necessary 
for inflammasome assembly and caspase-1 activation. Superoxide radicals are also known to 
modify redox-sensitive cysteines and can inadvertently inactivate caspase-1. This may provide 
temporal or dose dependent negative feedback of caspase-1 activity. 
We hypothesized that the timely and efficient resolution of gout is initiated early on by PMN-Ecto 
released by infiltrating neutrophils.  
 
Ectosomes, Complement and Coagulation 
 
Platelet ectosomes (PLT-Ecto) represent the largest population of circulating MV in blood (84). 
In the presence of plasma, PS expressed on the surface of PLT-Ecto can provide a catalytic 
surface for the assembly of the pro-thrombinase enzyme complex and initiate the coagulation 
cascade (85). Furthermore, thrombin can serve as an alternate C3/C5 convertase activating the 
complement system (86). Due to the cross-talk between coagulation and complement system, 
more clotting can translate to more inflammation. 
 
Platelets are responsible for primary hemostasis. The activation of platelet is accompanied by 
the translocation of PS to the membrane surface and the release of PLT-Ecto. PS on PLT-Ecto 
significantly enhances the pro-coagulant activity of platelets by binding components of the 
clotting cascade. The association of PS and clotting factors is based on the electrostatic 
interaction between positively charged γ-carboxyglutamic acid (GLA) domains of clotting factors 
and negatively charged PS on PLT-Ecto. Clotting factors that contain the GLA domain include 
VIIa (initiating complex), FIXa (intrinsic tenase complex) and FXa (pro-thrombininase complex). 
Collectively these factors initiate the intrinsic coagulation pathway resulting in the generation of 
thrombin. Systemic activation of clotting can lead to disseminated intravascular coagulopathy 
(DIC) which is initially characterized by overactive clotting system and compromised 
microcirculation (thrombotic microangiopathy) followed by overt bleeding due to the 
consumption of clotting factors and loss of clotting potential.  
Early studies demonstrated that the MV depletion prolonged the clotting time of human plasma 
and that activated platelets generated MV capable of supporting thrombin generation in platelet-
poor plasma (87, 88). The functional significance of PS and PLT-Ecto release for efficient 
clotting can be illustrated on patients with Scotts syndrome. These patients have a primary 
bleeding disorder caused by the inability of platelets to translocate PS to their surface and 
release PLT-Ecto (22).  
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 The release of PLT-Ecto can be induced by platelet stimuli such as thrombin or ADP. The 
vesiculation response is, however, much stronger during complement activation on the surface 
of platelets (10). Platelets exposed to sub-lytic concentration of C5b-9 were shown to release 
large amounts of small membrane vesicles capable of binding factor Va and assembling the 
pro-thrombinase enzyme complex (23). This form of platelet activation may be relevant in 
idiopathic thrombocytopenic purpura (ITP), an autoimmune condition with antibodies against 
platelet surface antigens that would initiate classical complement pathway activation and C5b-9 
deposition (89). Alternatively, during T-cell depletion therapy with anti-thymoglobuins (ATG) 
which cross-react with platelet antigens (90). 
 
ATG is the purified IgG fraction of sera from rabbits immunized with thymocytes (Thymoglobulin, 
Genzyme) or Jurkat cells (ATG Fresenius, Fresenius-Biotech). It is used in hematopoietic stem 
cell transplantation (HSCT) conditioning regimens to prevent graft vs. host disease (GvHD) or in 
kidney transplantation (NTX) as prevention or rescue treatment of acute rejection. ATG therapy 
is accompanied by various complications that include systemic activation of the coagulation 
system. Given that ATG recognizes platelet antigens, we hypothesized that ATG activates 
complement on the surface of platelets and induces the release of pro-coagulant PLT-Ecto, 
which accelerate clotting and cause thrombophilia.  
 
Erythrocytes (RBC) release RBC-Ecto under same conditions. Clinically antibody recognition of 
RBC and subsequent complement attack is an unlikely event that would only occur when ABO 
incompatible blood was transfused. During the storage of RBC in transfusion units RBC 
undergo a range of biochemical and structural changes that include the formation of RBC-Ecto 
(18, 91, 92). In fact, RBC lose 20% of their hemoglobin content in the form of RBC-Ecto during 
storage and these vesicles that accumulate are given in significant amounts to patients along 
with RBC at the time of transfusion (17). 
 
Clotting abnormalities with RBC transfusion are rare, but can be severe (93-96). Transfusion 
related acute lung injury (TRALI) is the most common cause of major morbidity and death after 
transfusion (97). The underlying mechanism of TRALI can be explained by the presence of 
contaminating leukocyte antibodies in the plasma of donor blood directed against human 
leukocyte antigens (HLA). The transfused anti-HLA antibodies target and activate neutrophils, 
which subsequently migrate to the lungs and compromise the pulmonary microcirculation. The 
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release of radicles and proteolytic enzymes by activated neutrophils damage the endothelial 
cells of lung capillaries. A pulmonary capillary leak syndrome develops resulting in pulmonary 
edema (98). Clinically TRALI presents as acute respiratory distress syndrome within 6h of 
transfusion. In 40% of TRALI patients, however, anti-leukocyte antibodies are absent in both the 
donor and recipient (99). The trigger for neutrophil activation in non-immune TRALI remains 
unknown.  
We hypothesized that the transfusion of pro-coagulant RBC-Ecto brings about a state of 
heightened clotting and inflammation due to systemic thrombin activation and C5a generation, 
which triggers neutrophil sequestration in lung microcirculation. 
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Aims and Objectives 
 
The aim of this thesis was to establish in vivo models of clinically relevant scenarios where 
micro-vesicle release alters the course of inflammation and provide mechanistic insights into 
disease pathophysiology. Specifically the aims were: 
 
1. To investigate the role of neutrophil microvesicles (PMN-Ecto) and complement 
activation in the initiation and resolution of gout.  
 
In the first project the aim was to establish a murine peritonitis model of gouty arthritis 
and determine whether PMN-Ecto are released by infiltrating neutrophils and whether 
they have an anti-inflammatory effect in vivo. Furthermore, we aimed to investigate the 
role of complement activation in gout. Specifically the ability of C5a to trigger PMN-Ecto 
release and in turn suppress the potentially priming effect of C5a on the inflammasome. 
Finally, we aimed to verify the presence of PMN-Ecto in joint exudates of patients 
undergoing an acute gout attack and confirm their anti-inflammatory effect in vitro.   
We hypothesized that PMN-Ecto constitute an early counter-regulatory signal that helps 
initiate the resolution of gouty inflammation and explain its self-limiting nature. 
 
2. To investigate the role of complement-induced platelet microvesicles (PLT-Ecto) release 
in the context of anti-thymoglobulin (ATG) induced coagulopathy. 
 
In the second project we set out to analyze whether ATG can induce complement 
dependent platelet activation, aggregation and PLT-Ecto release. Furthermore, we 
aimed to assess the ability of PLT-Ecto to activate the clotting cascade by assembling 
the pro-thrombinase complex. Finally, the aim was to correlate the activation of the 
complement and clotting system with the release of PLT-Ecto in patients receiving ATG.  
We hypothesize that ATG induces complement dependent platelet activation and 
release of PLT-Ecto. The release of these PLT-Ecto expressing PS then initiates 
systemic activation of the clotting system. 
 
3. To investigate the mechanism by which Red Blood Cell microvesicles (RBC-Ecto) 
induce activation of the complement system and amplify inflammation in the context of 
transfusion related complications.  
18
 In the third project, the aim was to establish a murine transfusion model using RBC-Ecto 
purified from aged erythrocytes and measure the degree of inflammation after 
transfusion. Specifically we aimed at measuring systemic thrombin and C5a generation, 
IL-6 release and pulmonary leukocyte sequestration.   
We hypothesized that RBC-Ecto derived from aged RBCs amplify systemic inflammation 
by thrombin dependent activation of C5 complement factor. 
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Figures 
 
 
 
Figure 1. 
Exosomes and ectosomes are microvesicles budding from a membrane. (a) Exosomes are 
produced by inward budding into the late endosomal compartment, called multi-vesicular bodies 
(MVB). When MVB fuse with the cell membrane, exosomes are released as preformed vesicles. 
(b) Ectosomes are small membrane vesicles shed by many cells by budding directly from the 
cell membrane. (100) 
 
 
 
 
  
20
 
 
Figure 2.  
Mechanisms regulating IL-1β production. Generation of IL-1β requires a priming signal, often 
from PRRs such as TLRs that activate NF-κB and NF-κB-dependent transcription of pro-IL-1β. 
The pro-IL-1β is then cleaved into the active, mature 17 kDa cytokine by caspase-1. NLR 
containing inflammasomes activate caspase-1. NLRs such as NLRP3 oligomerize upon 
activation (by danger signals such as those shown in the box) and recruit the adapter molecule 
ASC that subsequently recruits and activates caspase-1.(101) 
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Figure 3.  
Models of NLRP3 inflamamsome activation. The activation of NLRP3 has been shown to 
involve the ATP-gated P2X7R, pore-forming molecules or particulate ligands. Stimulation of 
P2X7R by extracellular ATP induces the activation of a cation channel that mediates potassium 
efflux. In addition, P2X7R activation promotes opening of the pannexin-1 pore, which may 
enable the cytosolic delivery of microbial molecules such as MDP. How particulate ligands 
activate NLRP3 is less clear. There is evidence that it may involve generation of ROS and 
additional studies suggest that destabilization of the lysosomal membrane and activation of the 
lysosomal protease cathepsin B (in the case of silica, urate crystals and fibrillar β amyloid) are 
critical. (101) 
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Abstract  
 
Gout is a highly inflammatory but self-limiting joint disease induced by the precipitation of 
monosodium urate crystals (MSU). While it is well established that inflammasome activation by 
MSU mediates acute inflammation, little is known about the mechanisms controlling its 
spontaneous resolution. Here we found in a murine peritonitis model that neutrophil-derived 
microvesicles (ectosomes) resolve acute MSU-driven inflammation. The release of IL-1β 
following MSU stimulation was dependend on generation of complement C5a. Neutrophils 
(PMN) infiltrating the peritoneum in response to C5a released phosphatidylserine (PS)-positive 
ectosomes early on in the course of inflammation. Treatment of the peritoneum with these 
ectosomes in turn resulted in suppression of IL-1β release and translated in a decrease in PMN 
influx. Ectosome-mediated suppression could be reproduced using PS-expressing liposomes 
and required the presence of the PS-receptor MerTK. In addition, ectosomes triggered the 
release of TGFβ independent of MerTK. TGFβ, however, was not sufficient to control MSU-
driven inflammation in vivo. Finally, neutrophil-derived microvesicles from joint aspirates of 
patients with gouty arthritis had similar anti-inflammatory properties. Ectosome-mediated control 
of inflammasome-driven inflammation is a compelling concept of autoregulation initiated early 
on during PMN activation in gout. 
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Introduction 
 
Gout is a highly inflammatory arthritis induced by the precipitation of monosodium urate crystals 
(MSU) in articular joints. Even without intervention, an acute gouty arthritis usually resolves 
spontaneously within a few days leaving minimal residual damage to the joint. What drives this 
timely resolution of gout, however, is not yet clear. 
 
The early inflammatory phase of gout is characterized by the production of the pro-inflammatory 
cytokine IL-1β and the infiltration of neutrophils into the joint space. IL-1β is the principle driving 
force of gouty inflammation and is released as a consequence of NALP3 inflammasome 
assembly and caspase 1 activation (1). The underlying mechanism behind the resolution of gout 
must therefore interfere with the release of IL-1β.    
 
Previous studies indicate that the generation of apoptotic leukocytes and their clearance by 
macrophages may play a key role in resolving gout (2, 3). Both the recognition of 
phosphatidylserine (PS) on the surface of apoptotic cells and the release of TGFβ upon their 
clearance are strong anti-inflammatory cues that can suppress an inflammatory response (4). 
PS-positive surfaces can engage the MerTK receptor initiating the transcription of suppressor of 
cytokine signaling (SOCS) 3 (5-7). High levels of SOCS3 expression in synovial tissues as well 
as elevated levels of TGFβ in the synovial fluids of patients during the resolution phase of gout 
have been reported (8). Little is however known about how and where the inflammasome is 
regulated. 
 
We previously established that human neutrophils stimulated by complement C5a or bacterial 
peptide (formyl-Methionyl-Leucyl-Phenylalanine, fMLP) in vitro release microvesicles 
(ectosomes) from their surface (9). These ectosomes express PS and are capable of inducing 
the release of TGFβ by monocyte-derived macrophages. In vitro, neutrophil-derived ectosomes 
have been shown to suppress the response to TLR ligands in monocyte-derived macrophages 
and dendritic cells (10). 
 
The aim of this study was to determine whether the anti-inflammatory effects of ectosomes 
extend to the NALP3 inflammasome, whether ectosomes are found in vivo and whether they 
take part in the early resolution of gouty inflammation. 
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 Results 
 
Bone marrow-derived ectosomes (BM-Ecto) suppress inflammasome activation in vitro. We first 
set out to find a source of murine ectosomes using B6 wild-type bone marrow cells as a close 
approximation of neutrophils. BM-Ecto were isolated by sequentially centrifuging supernatants 
of bone marrow cells stimulated with fMLP. Flow cytometric analysis identified intact vesicles 
that were able to retain CFSE. Further characterization revealed the expression of the 
neutrophil marker Gr-1 and surface exposure of phosphatidylserine (PS, assessed by staining 
with annexin V) on approximately 70-80% of intact BM-Ecto (Figure 1A). Consistent with data 
from human neutrophil-derived ectosomes (9), electron microscopy of BM-Ecto preparations 
revealed round shaped vesicles with a size of 50-500 nm (Figure 1B).   
We next asked whether BM-Ecto suppress MSU-induced inflammasome activation of resident 
peritoneal macrophages in vitro. Inflammasome activation in vitro is a two-step process that 
requires priming with a TLR ligand (LPS) (11) prior to stimulation with a specific inflammasome 
activator (MSU) (Figure 1C). Whereas up-regulation of pro-IL-1β and NALP3 components in 
cells is the measure of successful priming (Figure 1D), release of mature IL-1β along with the 
caspase 1 sub-units p20 or p10 defines efficient inflammasome stimulation (1, 12, 13). To 
determine whether BM-Ecto interfere with inflammasome activation, BM-Ecto were given to 
macrophages either prior to LPS priming or prior to stimulation with MSU (Figure 1E) once all 
LPS priming events (pro-ILβ and NALP3 upregulation) had taken place (Figure 1D).  
The release of IL-1β into culture supernatants was significantly suppressed when macrophages 
received BM-Ecto either prior to LPS priming or MSU stimulation (Figure 1F), indicating that 
BM-Ecto acted on both phases of inflammasome activation. Immunoblots of cell extracts (Figure 
1G, XT) and cell culture supernatants (Figure 1G, SN) revealed that when macrophages were 
co-incubated with BM-Ecto prior to LPS, they did not undergo efficient priming (less NALP3 and 
pro-IL-1β expression) and subsequently failed to respond to MSU stimulation (no Caspase 1 
p20/10 and IL-1β release). The addition of BM-Ecto after LPS priming resulted in partial 
suppression of the MSU response (no Caspase 1 p20 and less IL-1β), consistent with data 
obtained by ELISA (Figure 1F). These results indicated that BM-Ecto contain inflammasome 
activation in vitro by suppressing LPS priming and MSU stimulation independently of each 
other. 
The anti-inflammatory effects of Ecto have been attributed to their surface expression of PS (14) 
analogous to what has been reported for apoptotic cells (4, 5, 7). We therefore asked the 
question whether the in vitro effects of BM-Ecto could be reproduced by size-matched 
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liposomes expressing PS. Following our in vitro stimulation protocol (Figure 1E) macrophages 
were treated with equimolar (75nM) amounts of PS or control phosphatidylcholine (PC) 
liposomes prior to stimulation with MSU crystals. While PS liposomes interfered with LPS 
priming (Figure 1H and I, XT) and MSU stimulation (Figure 1H and I, SN), PC liposomes failed 
to attenuate the inflammasome response at any level. These results suggested that PS is 
involved in the inhibition of inflammasome activation by BM-Ecto.     
Inflammasome activation in macrophages is functionally limited by low expression of pro-IL-1β 
and therefore requires some form of priming (1, 13, 15). During gout, the activation of the 
NALP3 inflammasome, however, occurs in a sterile environment and has been shown to be 
independent of Toll-Like-Receptor 4 (16). Therefore the use of LPS as a priming agent may be 
purposeful in vitro, but does not accurately reflect what occurs in vivo. 
 
C5a and MSU-induced inflammation. MSU crystals are known to activate complement by 
assembling a functional C5 convertase complex at the crystal surface, which results in the 
generation of active C5a (17). C5a fragments have been reported to activate NFκB (18-20). 
Given that the injection of MSU alone can trigger IL-1β release, we hypothesized that C5a 
generated by MSU is responsible for inflammasome priming in vivo.  
Following the previously outlined in vitro protocol (Figure 1E), BM-Ecto were capable of 
suppressing IL-1β release from macrophages primed with C5a and stimulated with MSU (Figure 
2A) or macrophages stimulated by MSU in the presence of normal mouse plasma (NMP) 
(Figure 2B). MSU crystals in the presence of normal mouse plasma (NMP) generated C5a, 
which in turn primed the inflammasome via the C5aR leading to the release of IL-1β upon MSU 
stimulation of macrophages in vitro (Figure 2C). These results suggested that C5a is essential 
for inflammasome activation by MSU and that BM-Ecto inhibit C5a-mediated inflammasome 
priming. 
To study inflammasome activation in vivo, we next adopted a murine model of MSU-induced 
peritonitis (21). First we set out to analyze the course of the inflammatory response following 
intraperitoneal injection of MSU. We identified an almost immediate and steep rise of C5a 15min 
after introducing MSU into the peritoneum (Figure 2D). The generation of C5a was followed by 
the release of IL-1β into both the peritoneum and peripheral blood peaking 4 hours after MSU 
injection (Figure 2D-E). The release of C5a and IL-1β triggered a rapid rise in blood neutrophils 
(Figure 2E), which then infiltrated the peritoneal compartment reaching a maximum 14 hours 
after stimulation (Figure 2D). In accordance with our in vitro results, the release of IL-1β in 
response to MSU was significantly impaired in C5aR deficient mice (Figure 2F). 
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Our second objective was to determine whether Ecto are released by infiltrating neutrophils 
during MSU-induced peritonitis. At various time points following MSU stimulation, Ecto were 
isolated from peritoneal lavages by sequential centrifugation. Using flow cytometry, surface 
staining with annexin V and anti-Gr-1 identified them as PS-positive microvesicles of neutrophil 
origin (Figure 2G). These neutrophil ectosomes (PMN-Ecto) were found to be present in 
significant numbers, reaching up to 1,5x107 in the peritoneum 8 hours after MSU stimulation 
(Figure 2D). The kinetics of PMN-Ecto suggested that their release is an early event of 
neutrophil activation. 
 
Administration of Ecto attenuates MSU-induced inflammation in vivo. To determine whether 
Ecto have anti-inflammatory properties in vivo, the peritoneal compartment was pre-treated with 
2x107 Ecto 2 hours prior to the intraperitoneal injection of MSU. The Ecto used to pre-condition 
the peritoneum were either BM-Ecto isolated from ex vivo stimulated bone marrow cells or 
PMN-Ecto isolated from the lavage fluid of MSU-inflamed peritonea. The quantity (2x107) of pre-
injected BM- and PMN-Ecto corresponded to the maximum number of PMN-Ecto recovered 
during MSU-induced peritoneal inflammation (Figure 2D). 
Pre-treatment with PMN- or BM-Ecto resulted in a two to threefold suppression of IL-1β (Figure 
3) release in response to MSU in the peritoneum (Figure 3A) and peripheral blood (Figure 3B). 
This early suppression of inflammation translated into less pronounced neutrophilia in blood 
(Figure 3C) and subsequently a threefold decrease in the number of neutrophils infiltrating the 
peritoneum 14 hours after stimulation (Figure 3D). Taken together, these results indicated that 
Ecto from two independent sources can suppress local and systemic inflammation induced by 
MSU.  
 
The in vivo effects of Ecto can be mimicked by liposomes expressing phosphatidylserine (PS). 
To confirm that PS liposomes can act as a surrogate for Ecto in vivo, approximately 1x108 PS or 
control PC liposomes were injected intraperitoneally instead of Ecto 2 hours prior to stimulation 
with MSU. Pre-treatment with PS liposomes resulted in suppression of pro-inflammatory 
cytokines (Figure 4A-B), blood neutrophilia (Figure 4C) and neutrophil influx into the peritoneum 
(Figure 4D) in response to MSU. Injection of control PC liposomes failed to achieve an anti-
inflammatory effect. 
 
Suppression by BM-Ecto is MerTK-dependent in vivo. To directly test the involvement of PS in 
Ecto-mediated immunosuppression, we next applied our model to mice lacking the MerTK 
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receptor (MerTK-/-) which is known to bind PS and relay its signal by inducing suppressor of 
cytokine signaling (SOCS) 3 (7). 
The peritonea of MerTK-/- and control B6129S wild-type mice were pre-treated with BM-Ecto 
prior to MSU stimulation. Whereas pre-treatment of wild-type mice with BM-Ecto led to 
suppression of cytokines in both peritoneum (Figure 5A) and peripheral blood (Figure 5B), the 
anti-inflammatory effects of BM-Ecto were absent in MerTK-/- mice. The same pattern emerged 
with regard to blood neutrophilia (Figure 5C) and peritoneal accumulation of neutrophils (Figure 
5D). Furthermore, 4 hours after intraperitoneal BM-Ecto injection, we observed a MerTK-
dependent induction of SOCS3 in peritoneal macrophages (Figure 5E). Of note, inflammation 
induced by MSU in MerTK-/- mice was significantly higher compared to background-matched 
wild-type mice (Figure 5A-D), suggesting that in wild-type mice endogenously released PMN-
Ecto limit the magnitude of MSU-induced inflammation via MerTK.  
 
BM-Ecto induce the release of TGFβ. It has been suggested that TGFβ participates in the 
resolution of gout in its late stages (22). Therefore, we next asked whether Ecto induce the 
release of TGFβ in vivo. Injection of BM-Ecto induced the release of TGFβ in the peritoneum 
(Figure 6A). The release of TGFβ was further enhanced when BM-Ecto primed mice received 
MSU (Figure 6A). Since BM-Ecto themselves were not the source of TGFβ (Figure 6B) and the 
amount of TGFβ released in vitro by peritoneal macrophages remained the same regardless of 
inflammasome activation (Figure 6C), we hypothesized that the additive effect of MSU and BM-
Ecto on TGFβ release could be due to infiltrating cells responding to BM-Ecto. Indeed, 
monocytes and neutrophils isolated from MSU inflamed peritonea were able to release TGFβ in 
response to BM-Ecto in vitro (Figure 6D). To determine which of these cells contributes the 
most to the TGFβ pool in vivo, resident macrophages, infiltrating monocytes and neutrophils 
from BM-Ecto-treated peritonea were stained for latency associated peptide (LAP). LAP is part 
of latent TGFβ and remains tethered to the surface of macrophages (23) and monocytes (24) 
once TGFβ is released and cleaved into its active form. Whereas expression of LAP in naive 
resident peritoneal macrophages (F480+, CD115+, Ly6C-) was low, LAP progressively increased 
over time after intraperitoneal injection of BM-Ecto, indicating continuous TGFβ release (Figure 
6E). Monocytes and neutrophils are not present in untreated peritonea. Upon i.p. MSU 
stimulation, however, infiltrating monocytes (Ly6C+, F480-, Ly6G-) and, to a lesser extent, 
neutrophils (Ly6C+, F480-, Ly6G+) up-regulated LAP when the peritoneum was pre-treated with 
BM-Ecto prior to MSU (Figure 6E). 
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Ecto suppress MSU-induced peritonitis independent of TGFβ. We next asked whether TGFβ 
was necessary for the suppressive effects of Ecto. In vitro, TGFβ release was found to be 
independent of MerTK (Figure 6F). Significant increases in TGFβ were consistently measured in 
the peritoneum of both wild-type and MerTK-/- mice pre-treated with BM-Ecto (Figure 6G). Of 
note, PS liposomes did not induce TGFβ release in vivo (Figure 7H). Since PS liposomes 
attenuated the response to MSU (Figure 4) without inducing TGFβ and BM-Ecto failed to inhibit 
inflammation in MerTK-/- mice (Figure 5) despite releasing TGFβ (Figure 6G), TGFβ did not 
seem to be necessary for BM-Ecto-mediated resolution of acute gouty inflammation. To confirm 
that the effect of BM-Ecto was independent of TGFβ, neutralizing anti-TGFβ1 antibody (100µg) 
was given i.p. 30min prior to BM-Ecto. In the presence of TGFβ1-blocking antibody, BM-Ecto 
still retained their capacity to suppress inflammation (Figure 6I). Although the blocking of TGFβ1 
slightly increased neutrophil influx in response to MSU suggesting that TGFβ may play a role 
(Figure 6I), the injection of 1µg recombinant mouse TGFβ1 instead of BM-Ecto had not effect 
(Figure 6J).  
Taken together, these data suggested that Ecto inhibit the acute inflammatory response to MSU 
predominantly via the PS-MerTK pathway rather than TGFβ. Although Ecto induced the release 
of TGFβ by macrophages and monocytes, MerTK alone was necessary and sufficient for Ecto 
to suppress inflammasome activation in vivo. 
 
PMN-Ecto are present in synovial exudates during gouty inflammation in humans. Lastly, we 
sequentially centrifuged synovial exudates of gouty arthritis (GA) and control osteoarthritis (OA) 
patients to verify the presence of microvesicles during gouty attacks in humans. Arthrocenthesis 
was performed within 1 day after the onset of symptoms. Using flow cytometry, we found 
annexin V-positive vesicles expressing the granulocyte marker CD66b and the neutrophil-
specific enzyme myeloperoxidase (MPO) (Figure 7A). Electron micrographs (Figure 7B) of 
exudates confirmed the presence of intact vesicles that were approximately 50 nm in size. 
The amount of PMN-Ecto isolated from gout exudates correlated with the number of infiltrating 
PMN (Figure 7C) and gouty arthritis (GA) exudates had significantly higher numbers of PMN-
Ecto compared to osteoarthritis exudates (Figure. 7D). Recovery of neutrophil-derived 
microvesicles from synovial exudates of patients during gouty inflammation suggested that 
PMN-Ecto release occurs and is relevant in vivo. 
In vitro, PMN-Ecto from gout exudates (Gout-Ecto) were able to induce the release of TGFβ 
from human monocyte-derived macrophages (Figure 7E) and inhibited the release of IL-1β by 
macrophages (Figure 7F) treated as outlined in Figure 1E. Furthermore, in the presence of 
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normal human plasma (NHP), MSU crystals were able to simultaneously prime and stimulate 
the inflammasome. Consistently, MSU failed to prime the inflammasome in the presence of heat 
inactivated or C5-blocked plasma, confirming that priming is C5-dependent (Figure 7G). Finally, 
Gout-Ecto suppressed IL-1β release in macrophages stimulated by MSU in the presence of 
NHP (Figure 7H).  
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Discussion 
 
The major finding of the present study is that PMN-Ecto are rapidly released by infiltrating 
neutrophils in a murine model of gout and that these ectosomes participate in the control of 
inflammation induced by MSU crystals. Ectosomes achieve their anti-inflammatory effect by 
engaging the MerTK receptor. The regulation induced by PMN-Ecto starts almost immediately 
after the influx of cells into the peritoneum, indicating that the control of inflammation starts 
much earlier than presumed until now. Interestingly, the very cells that are responsible for acute 
inflammation (i.e. neutrophils), act also as its regulator due to the shedding of ectosomes. 
The release of PMN-Ecto is an early phenomenon of neutrophil activation (9). In our gout 
model, PMN-Ecto were released as early as 2 hours after intraperitoneal injection of MSU and 
their concentration peaked at 8 hours. To analyze the effect of Ecto on gouty inflammation, Ecto 
were given intraperitoneally prior to MSU injection. The number of Ecto injected was 
physiological and the amount was set at the maximum number of PMN-Ecto recovered from the 
peritoneum after MSU stimulation. Since Ecto bind back to cells (9) and are continuously 
cleared (25), the recovery of 1.5x107 Ecto is likely an underestimation of the total amount of 
PMN-Ecto shed during the course of MSU peritonitis. Ecto were generated from two alternate 
sources, from bone marrow cells and neutrophils. Although BM-Ecto were an approximation of 
neutrophil-derived Ecto, they shared the same phenotype as PMN-Ecto (not shown) and were 
equally effective in suppressing inflammation. In addition to isolating Ecto from peritoneal 
exudates in our gout model (Figure 2D), the presence of PMN-Ecto was confirmed in synovial 
aspirates of patients undergoing an acute gouty attack (Figure 8), further supporting their in vivo 
relevance. 
 
Previous studies have already suggested that PS expressed on apoptotic cells (3-5, 7) and 
ectosomes (26) contribute to the resolution of inflammation. PS has been shown to mediate 
anti-inflammatory signals via the MerTK receptor (5, 7). MerTK activation leads to induction of 
SOCS3 (6) and in turn to suppression of TLR-induced cytokine release (5, 7, 14). Whether the 
NALP3 inflammasome is subject to the same regulatory mechanism has not yet been shown. In 
accordance with these studies, we could confirm that PS-expressing Ecto suppress LPS priming 
of the NALP3 inflammasome in vitro (Figure 1F-G). LPS priming, however, is not required for 
the inflammatory response to MSU in vivo and is merely used to model inflammasome 
activation in vitro (27). In addition to activating the inflammasome, MSU crystals activate the 
complement cascade by assembling a C5 convertase on their surface (17). We could identify 
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C5a generated by MSU as the main inflammasome priming agent in gout. The anti-inflammatory 
effect of PMN-Ecto was therefore not limited to the inhibition of TLR stimuli, but extended to C5a 
and C5aR signaling as well. Furthermore, C5a was able to both prime the inflammasome and 
limit its activation by inducing the release of PMN-Ecto, thus forming the basis of an auto-
regulatory negative feedback loop in gout (9).  
Whereas studies using liposomes suggested that PS-positive vesicles could down-regulate 
inflammation, involvement of PS was confirmed in mice deficient for the PS receptor MerTK. 
Furthermore, the higher degree of inflammation in MerTK-/- compared to wild-type mice 
suggested that PS expressed on Ecto provides baseline suppression in gouty inflammation. Of 
note, high expression of SOCS3 in synovial tissue has been found in patients during the acute 
phase of gout (8), further supporting the notion that the PS-MerTK axis plays a role in limiting 
gouty inflammation. 
 
TGFβ is regarded as the prime mediator in the active resolution of gout (8, 28, 29). Levels of 
TGFβ have been found to progressively increase in synovial fluids of gout patients after an 
attack, suggesting that TGFβ may be involved in late phases of resolution (8, 22). We 
demonstrated that Ecto trigger the release of TGFβ in vitro and in vivo. These findings are 
consistent with other studies that have shown release of TGFβ by macrophages (4) or 
neutrophils (3) in response to apoptotic cells and Ecto (26). In vivo, however, neither treatment 
with recombinant mouse TGFβ1 (Figure 6J), nor the release of TGFβ by Ecto in the absence of 
PS-MerTK activation (Figure 5D,6G) was sufficient to control the acute inflammatory response 
to MSU. Furthermore PS-liposomes alone could reproduce the Ecto effect without inducing the 
release of TGFβ (Figure 4,6H) and TGFβ blocking did not compromise the ability of BM-Ecto to 
suppress inflammation (Figure I). These findings argue against a role for TGFβ in the early 
phase of gout. Given that gout patients with TGFβ polymorphisms frequently progress to more 
advanced disease states, TGFβ may play a role in chronic gout and affect the rate of 
progression rather than resolution of acute attacks (30). 
Aside from Ecto affecting macrophages, other cell types may have been involved in the 
observations made in our model. For instance, endothelial cells are critically involved in 
mediating neutrophil extravasation. Recent studies have demonstrated a crucial role for IL-1β-
induced endothelial cell activation for neutrophil transmigration in MSU peritonitis (27). As 
MerTK is expressed on endothelial cells (31) and TGFβ is known to inhibit endothelial cell 
activation in vitro (28), it cannot be ruled out that the effect of Ecto on inhibiting neutrophil influx 
in vivo was in part mediated by the suppression of endothelial cell activation. Furthermore, other 
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mediators associated with PMN-Ecto, such as Annexin A1 and resolvins, may contribute to the 
resolution of gouty inflammation (Dalli et al., 2008; Dalli and Serhan, 2012).  
 
The motivation behind this work was to better understand the self-limiting nature of gout. This 
study supports the notion that resolution of gout is initiated with the release of PMN-Ecto early 
on during neutrophil activation. In a broader context, PMN-Ecto release may limit excessive 
inflammation in response to both exogenous and endogenous danger signals and their 
pathophysiological relevance likely extends to conditions other than gout. 
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Materials and Methods 
 
Mice. C57BL/6 (B6) and Balb/c mice were bred at the institution’s animal facility or purchased 
from Charles River (Sulzfeld, Germany). B6;129-Mertktm1Grl/J (MerTK-/-) and the respective 
wild-type strain B6;129SF2/J were obtained from The Jackson Laboratories (Bar Harbour, MN, 
USA). C.129S4(B6)-C5ar1tm1Cge/J (C5aR-/-) mice on a Balb/c background were a generous 
gift from Prof. van den Broek (Institute of Experimental Immunology, University of Zürich). All 
mice were housed in a specific pathogen-free environment and were used between 6 and 12 
weeks of age. Animal care and experimentation were performed in accordance with national 
guidelines (Federal Veterinary Office) and had been approved by the local government 
authorities.  
 
Reagents and Antibodies. Fluorochrome-conjugated antibodies against CD11b (clone M1/70), 
Gr-1 (RB6-8C5), Ly6C (AL-21), Ly6G (1A8), CD115 (AFS98), F4/80 (BM8), CD45 (30F11), 
CD66b (G10F5), MPO (MPO455-8E6) and LAP were from Biolegend (San Diego, CA, USA). 
Purified anti-CD16/32 (Fc-Block, 2.4G2) was from BD Pharmingen (Allschwill, Switzerland) and 
AnnexinV-APC was from Immunotools (Friesoyte, Germany). 7-AAD and CFSE were from 
Invitrogen (Zug, Switzerland), monosodium urate and fMLP from Sigma (Schnelldorf, Germany). 
Anti-IL1β (AF-401-NA), anti-TGFβ (9016) was from R&D, anti-NALP3 (Cryo-2) and anti-caspase 
1 p20 (Casper-1) antibodies were from Adipogen (Liestal, Switzerland), anti-actin (C4), anti-
TGFβ (H-112), anti-SOCS3 (H-103) and HRP conjugated anti-mouse (sc-2005), -rabbit (sc-
2004) and -goat (sc-2020) antibodies were from Santa Cruz Biotechnology (Muttenz, 
Switzerland). Anti-C5 antibody (Eculizumab®) was a generous gift from Alexion Pharmaceuticals 
(Lausanne, Switzerland). 
 
Generation of MSU crystals. MSU crystals were prepared by dissolving 0.5g of MSU in 90ml de-
ionized H20 and 600µl of 5M NaOH. This MSU solution was heated to 90°C, passed across a 
0.2µm filter and allowed to precipitate into crystals over-night at room temperature. The slurry 
was subsequently washed with ethanol twice and acetone once, which was then allowed to 
evaporate leaving crystals behind. Crystals were stored at  -20°C and dissolved in 0.9% NaCl at 
6mg/ml prior to use. Size of MSU crystals was verified by transmission light microscope 
(Olympus, IX50) at room temperature and acquired by Cell Sense Standard software. 
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Generation and analysis of PMN-Ecto and BM-Ecto. Mouse PMN-Ecto were derived from 
inflamed peritonea. 6-10h after i.p. injection of 3mg MSU crystals, the peritoneal cavity was 
lavaged with 5ml PBS-1%FCS and the lavage fluid was then sequentially centrifuged to 
separate cells (350g/10’/4°C), cell debris (3000g/10’/4°C) and finally PMN-Ecto 
(50.000g/40’/4°C). The final pellet was diluted in 0.2µm filtered PBS or AnnexinV-staining buffer 
(BD), stained with fluorochrome-tagged AnnexinV and anti-Gr-1 and phenotyped by flow 
cytometry. In some experiments SSC threshold above Annexin buffer background was applied. 
To quantify PMN-Ecto, defined amounts of 4.3 µm fluorescent beads (Trucount tubes, BD) were 
added to the staining solution. The number of PMN-Ecto was determined as follows: (% of total 
microvesicles / % of Trucount beads) x (absolute no. of beads) x (% of AnnexinV+, Gr-1+ double 
positive events). Flow cytometric analysis was performed using a CyanADP cytometer 
(Beckaman Coulter, Nyon, Switzerland) and data were analyzed using FlowJo Software 
(TreeStar, San Jose, CA, USA). Mouse BM-Ecto were prepared from bone marrow cells, which 
were obtained by flushing femurs and tibias of B6 mice. Erythrocytes were removed by 
hypotonic lysis and the remaining myeloid cells stimulated with 1µM fMLP in RPMI for 30min at 
37°C. The supernatant was sequentially centrifuged as above and BM-Ecto were phenotyped 
by flow cytometry with fluorochrome-tagged AnnexinV and anti-Gr-1. Alternatively, BM-Ecto 
were pre-stained with CFSE and only CFSE+ vesicles were further analyzed. Human PMN-Ecto 
were isolated by sequentially centrifuging synovial exudates from patients with confirmed gouty 
attacks. These PMN-Ecto were phenotyped as AnnexinV+, CD66b+, MPO+ vesicles.  
 
Generation of PS/PC liposomes. Unilamelar liposomes, composed of either L-α-phosphatidyl-
choline (PC, derived from bovine liver) alone or PC together with equimolar concentrations of L-
α-phosphadityl-serine (PSPC, derived from porcine brain, both Avanti Polar Lipids, Alabaster, 
USA) were prepared according to the repeated freeze-thawing method (32). Briefly, the 
individual phospholipids, stored in chloroform, were added to glass tubes and the chloroform 
was evaporated. After adding PBS, the lipid mixture was vortexed for 5 min, subjected to five 
freeze-thaw cycles, and subsequently extruded eight times using a nucleopore polycarbonate 
filter (0.2 mm; VWR, San Diego, CA). Final liposome concentration of each preparation was 
adjusted at 16 mM as measured by a standard phosphate assay. This protocol yielded 
liposomes of 100 nm diameter as determined by electron microscopy and zetasizer (DelsaTM 
NanoC).  
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Electron microscopy. Microvesicles were fixed in 1% glutaraldehyde (final concentration) for 1 
min at room temperature. They were then adsorbed to parlodion-coated copper grids. After 
washing, samples were stained with 2% uranylacetate before being observed in a Philips 
Morgani 268 D transmission electron microscope operated at 80 kV. 
 
Cell culture conditions, ELISA and western blot. Resident peritoneal macrophages were 
harvested from the indicated mouse strains by peritoneal lavage and plated at a density of 
2x106/well. To achieve full inflammasome activation in vitro, cells were first primed with 10ng/ml 
ultra-pure LPS (Invivogen, catalogue code: tlrl-3pelps) or 10ng/ml mouse recombinant C5a (BD) 
for 10h, washed and subsequently stimulated with 100µg/ml MSU. Macrophages were treated 
with BM-Ecto (1x108/2x106 macrophages), PS- or PC-liposomes (75nM, approximately 
1x108/2x106 macrophages) for 10min either prior to LPS priming or prior to MSU stimulation. 
Cell extracts and cell culture supernatants were prepared for western blotting as described 
previously (33). Cells were lysed with RIPA buffer and lysates denatured at 95°C/10min in 
reducing sample buffer (Pierce). Cell supernatants were concentrated by TCA/Acetone protein 
precipitation and denatured in Laemmli buffer with added 2-ME. All samples were resolved with 
Tris-Gly SDS PAGE (Any-KDTM TGXTM precast gels, Biorad) and transferred to PVDF 
membrane (Immobilon PSQ, Millipore). Proteins were probed in blocking buffer (PBS, 0.05% 
Tween 5% non-fat milk) and developed by ECL detection reagents (Pierce). Pro-IL-1β, NALP3 
and SOCS3 (Figure 1D, 5E) protein expression was analyzed by densitometry using Image 
Lab™ software (Biorad) and normalized to actin. 
Cell culture supernatants, peritoneal lavages and serum samples were harvested at the 
indicated time points and cytokines analyzed by ELISA according to the manufacturer’s 
instructions. IL-1β and IL-6 OptEIA kits were from BD Pharmingen and TGFβ1 was from 
eBiosciences. 
Human monocyte derived macrophages (HMDM) were isolated from buffy coats of healthy 
blood donors as described (26). Briefly, buffy coats were diluted 1/1(vol/vol) in HBSS, layered 
over Ficol-Histopaque (Sigma, St Louis, USA) and centrifuged 350g/25min/25°C with no breaks. 
The PBMC’s were collected at the ficol gradient interphase, washed with PBS-2mMEDTA and 
MACS buffer (Miltenyi, Bergisch Gladbach, Germany). Monocytes were enriched by anti-CD14 
magnetic beads (Miltenyi) according to manufacturer’s instructions and allowed to mature into 
macrophages in tissue culture plates over 6-7days in DMEM 10% normal human serum. 
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Complement assays. C5a ELISA consisted of rat anti-mouse C5a IgG capture antibody (BD, 
558027) and rat anti-mouse C5a biotinylated detection antibody (BD, 558028) both used at 5 
µg/ml. PBS 10% FCS was the assay diluent and C5a was revealed with SA-HRP (BD). 
Recombinant mouse C5a (BD, 622597) was used as an ELISA standard and priming agent in 
vitro at 10ng/ml. Blood for the purpose of Normal mouse and human plasma were anti-
coagulated with Refludan (Celgene, Boudry, Switzerland) at final concentration of 2.5µg/ml. 
Human plasma was heat inactivated at 56°C for 30min and C5 was inhibited with 50µg/ml anti-
C5 blocking antibody (Eculizumab®) at 4°C for 30min.      
 
Experimental peritonitis. Mice were pre-treated with an intraperitoneal (i.p.) injection of either 
2x107 BM- or PMN-Ecto 2 hours prior to i.p. stimulation with 3mg MSU-crystals in 500µl of 0.9% 
NaCl. Control groups were given ectosomes followed by 0.9% NaCl or received the stimulus 
preceded by an injection of 0.9% NaCl instead of ectosomes. At the indicated time points 
following induction of peritonitis, mice were sacrificed by CO2-inhalation and peritoneal lavage 
was performed with 5 ml PBS 1% FCS. The lavage fluid was passed over a 70 µm filter, 
washed and contaminating red blood cells were removed by hypotonic lysis. Leukocytes were 
then counted with an automated cell counter (Beckman Coulter). Peripheral blood was obtained 
by cardiac puncture following sacrifice. Blood was drawn into 1ml syringes containing 100 U 
heparin, washed and red blood cells removed by hypotonic lysis. Blood leukocytes were 
counted using GLASSTIC slides (Hycor, CA, USA). Cellular phenotype of peritoneal and 
peripheral blood leukocytes was determined by flow cytometry following surface staining with 
the indicated antibodies (Figure S1). 
 
Patient samples. Synovial arthrocenthesis samples were obtained from patients included in the 
Basel COUGAR cohort study. The study had been approved by the local ethics committee. All 
patients had given written informed consent prior to inclusion in the study.  
 
Statistical analysis. All data are presented as mean ± SEM. Comparisons between treatment 
groups were performed using one-way ANOVA with Bonferroni’s multiple comparison post-
testing (Prism version 6; GraphPad Software). Significance was set at P < 0.05. 
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Figure legends 
 
Figure 1. Characterization and in vitro properties of BM-Ectosomes.  
(A) Bone marrow-derived ectosomes (BM-Ecto) were generated as indicated in Methods. 
Following labeling with CFSE, CFSE-positive events (representing intact vesicles) were further 
analyzed for surface expression of Gr-1 and phosphatidylserine (via annexin V binding) by flow 
cytometry (upper lane, left to right). BM-Ecto are CFSE-, Gr-1, annexin V-positive. Controls 
(lower lane, left to right) are: annexin buffer alone, CFSE threshold set on sonicated BM-Ecto 
previously stained with CFSE, isotype control for BM-Ecto stained with annexin V and IgG1 
isotype in PBS. Numbers are % positive events (B) Transmission electron microscopy of BM-
Ecto. Size bar is 100 nm. (C) MSU crystals in light microscope. Size bar 50µm. (D) Pro-IL1β 
and NALP3 expression in B6 peritoneal macrophages during LPS priming (10 ng/ml) in vitro 
assessed by immunoblot. Expression in arbitrary units of band intensity normalized to actin. (E) 
In vitro stimulation protocol. B6 peritoneal macrophages were primed with LPS for 10h, washed 
and subsequently stimulated with 100µg/ml MSU for 4h. BM-Ecto (1x108/2x106 macrophages) 
were given either prior (BM-Ecto+LPS>MSU) or after (LPS>BM-Ecto+MSU) LPS priming as 
outlined. Alternatively, PS- or control PC-liposomes (1x108/2x106 macrophages) were given 
instead of BM-Ecto. (F, H) IL-1β in supernatants determined by ELISA. n=4 per group. Mean ± 
SEM is shown. (G, I) Cell extracts (XT) and supernatants (SN) were analyzed for the presence 
of NALP3, pro-IL-1β, IL-1β and active caspase 1 (p20 and p10). Data are representative for 3 
independent experiments. ***P<0.001 using 1-way ANOVA and Bonferroni post test. 
 
Figure 2. C5a and MSU-induced inflammation. 
(A-B) Peritoneal macrophages of B6 mice were subjected to the inflammasome stimulation 
protocol as outlined in Figure 1E. For inflammasome priming, recombinant mouse C5a at 
10ng/ml (A) or 25% normal mouse plasma (NMP) (B) was used instead of LPS. IL-1β release, 
pro-IL-1β and NALP3 expression were analyzed by ELISA and western blot, respectively. n=6 
per group pooled from 2 independent experiments (ELISA), western blots representative of 2 
independent experiments. (C) C5a generation and IL-1β release by C5aR+/+ or C5aR-/- 
peritoneal macrophages stimulated with 100µg/ml MSU + 25% NMP for 10h in vitro. n=6 per 
group pooled from 2 independent experiments. ***P<0.001 using Students t-test. (D-E) B6 mice 
were injected with 3mg MSU intraperitoneally. At the indicated time points thereafter, peritonea 
were lavaged and infiltrating cells isolated. Peripheral blood was obtained by cardiac puncture. 
Concentrations of C5a and IL-1β were determined by ELISA in (D) peritoneal lavage fluid and 
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(E) plasma. PMN were phenotyped by flow cytometry as CD45+, CD11b+, Ly6C+, Ly6G+ cells in 
both (D) peritoneal lavage and (E) blood. n=4/time point pooled from 2 independent 
experiments. (F) IL-1β concentration in the peritoneal lavage of C5aR+/+ and C5aR-/- mice 4h 
after 3mg MSU i.p. injection. n=5 pooled from 2 independent experiments. (G) PMN-Ecto were 
identified as Annexin V+, Gr-1+ events by flow cytometry after sequential centrifugation of 
peritoneal lavage fluid. Counting of PMN-Ecto was carried out with beads as indicated in 
Methods. Mean ± SEM is shown. ***P<0.001 using 1-way ANOVA and Bonferroni post test. 
 
Figure 3. Administration of ectosomes attenuates MSU-driven peritoneal inflammation. 
B6 mice were injected intraperitoneally with 3mg MSU. Where indicated, mice were pre-injected 
i.p. with 2x107 BM- or PMN-Ecto 2h prior to MSU stimulation. Control groups received BM-
/PMN-Ecto injections i.p. followed by NaCl instead of MSU. IL-1β was determined by ELISA 4h 
after MSU stimulation in (A) peritoneal lavage fluid and (B) plasma. PMN counts in peripheral 
blood (C) and peritoneum (D) 4h and 14h after MSU stimulation, respectively, were determined 
as indicated in Figure 2D-E. n=6-8 per group pooled from at least 3 independent experiments, 
*P<0.05, **P<0.01, ***P<0.001 using 1-way ANOVA and Bonferroni post test. Mean ± SEM is 
shown. 
 
Figure 4. PS-liposomes mimic the anti-inflammatory effect of ectosomes in vivo. 
B6 mice were injected intraperitoneally with 3mg MSU. Where indicated, mice were pre-injected 
with 75 nM (approximately 1x108) of PS- or PC-liposomes i.p. 2h prior to MSU stimulation. 
Control groups received PS- or PC-liposome injections followed by NaCl instead of MSU. IL-1β 
was determined 4h after MSU stimulation in (A) peritoneal lavage fluid and (B) plasma. PMN 
counts in peripheral blood (C) and peritoneum (D) 4h and 14h after MSU stimulation, 
respectively, were determined as indicated in Figure 2D-E. n=6-8 per group pooled from at least 
3 independent experiments, *P<0.05, **P<0.01, ***P<0.001 using 1-way ANOVA and Bonferroni 
post test. Mean ± SEM is shown. n.s. = not significant. 
 
Figure 5. Ecto-mediated immunosuppression requires MerTK in vivo.  
B6/129S (WT) or MerTK-/- mice were injected i.p. with 3mg MSU. Where indicated, mice were 
pre-injected with 2x107 BM-Ecto i.p. 2h prior to MSU stimulation. IL-1β was determined 4h after 
MSU stimulation in (A) peritoneal lavage fluid and (B) plasma. PMN counts in (C) peripheral 
blood and (D) peritoneum 4h and 14h after MSU stimulation, respectively, were determined as 
in Figure 2D-E. n=6-8 per group, pooled from at least 3 independent experiments. (E) SOCS3 
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expression in peritoneal macrophages of B6/129S (WT) and MerTK-/- mice determined by 
immunoblot 4h after i.p. BM-Ecto injection. Expression of SOCS3 in arbitrary units of band 
intensity normalized to actin. n=2 per group pooled from 2 independent experiments. *P<0.05, 
**P<0.05 using 1-way ANOVA and Bonferroni post test. Mean ± SEM is shown. n.s. = not 
significant. 
 
Figure 6. Ecto induce the release of TGF-β. 
TGFβ in peritoneal lavage fluids of (A) B6 mice treated as outlined in Figure 3 was determined 
by ELISA. n=6-8 pooled from 3 independent experiments. (B) BM-Ecto lysates were assessed 
for TGFβ content by immunoblot. Recombinant mouse TGFβ was used as control. Release of 
TGFβ by B6 (C) resident peritoneal macrophages or (D) monocytes and neutrophils isolated 
from MSU-inflamed peritonea following treatment with C5a, MSU and/or BM-Ecto in vitro as 
outlined in Figure 2A. (E) Expression of latency associated peptide (LAP) on B6 macrophages, 
monocytes and neutrophils isolated either 4h after i.p. injection of BM-Ecto or 4h after i.p. 
injection of MSU with BM-Ecto pre-treatment. Controls received NaCl i.p. (untreated). (F) The 
release of TGFβ by WT and MerTK-/- macrophages treated with BM-Ecto in vitro. n=6/group. 
TGFβ in peritoneal lavage fluids of (G) B6/129S (WT) and MerTK-/- mice treated with BM-Ecto or 
(H) B6 mice treated with liposomes as outlined in Figures 3 and 4 ,respectively. n=6-8/group. (I) 
The effect of neutralizing TGFβ1 on peritoneal PMN influx using 100µg anti-TGFβ1 injected i.p. 
15min prior to MSU or 15min prior to BM-Ecto pre-treatment. *P<0.05, **P<0.01, ***P<0.001 
using 1-way ANOVA and Bonferroni post test. Mean ± SEM is shown. n.s. = not significant. 
 
Figure 7. PMN-Ecto are present in gout exudates in humans.  
Gout-Ecto isolated from joint aspirates of patients undergoing a gout attack. (A) Flow cytometric 
characterization of Gout-Ecto using annexin V, anti-CD66b and anti-myeloperoxidase (MPO) 
antibodies identified them to be of neutrophil origin. Counting was performed using microbeads. 
(B) Electron micrograph of Gout-Ecto. Size bar 1µm (left) and 100nm (right). (C) Correlation 
between the number of infiltrating PMN and Gout-Ecto found in gouty (GA) and osteoarthritis 
(OA) exudates. Each dot represents a single patient. Linear regression line and 95% confidence 
bands are indicated. (D) Concentration of Gout-Ecto in gout and osteoarthritis exudates. (E) 
Release of TGFβ by human monocyte-derived macrophages (HMDM) treated with Gout-Ecto 
(1x108 Gout-Ecto/2x106 macrophages). n=7 pooled from 2 independent experiments. (F) 
Suppression of IL-1β release by HMDM treated with Gout-Ecto following the in vitro protocol 
outlined in Figure 1E. (G) IL-1β release upon 14h stimulation of HMDM with 100ug/ml MSU in 
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25% normal human plasma (NHP), heat inactivated NHP (hiNHP) or C5-blocked NHP (αC5). (F-
G) n=6 pooled from 3 independent experiments. ***P<0.001 using 1-way ANOVA and 
Bonferroni post test. (H) Suppression of IL-1β release by HMDM treated with Gout-Ecto and 
stimulated as outlined in (G). (D,E,H) ***P<0.001 using Student’s t-test. Mean ± SEM is shown. 
 
Figure S1. Peritoneal exudate cells phenotype and gating strategy 
Phenotype of peritoneal exudate cells and blood leukocytes was determined by flow cytometry 
following surface staining of the indicated antibodies. Leukocyte populations were defined as 
follows: macrophages (F480+, CD115+, Ly6C-), neutrophils (Ly6C+, F480-, Ly6G+) and 
monocytes (Ly6C+, F480-, Ly6G-). 
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 Antithymocyte globulin-induced platelet prothrombinase 
activity is a consequence of complement activation and 
platelet microvesicle release.  
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 Abstract 
 
T cell depletion with antithymocyte globulins (ATG) can be complicated by thrombopenia and 
hypercoagulability. The underlying mechanism is still unclear. We found that binding of ATG to 
platelets caused platelet aggregation, alpha-granule release, membrane phosphatidylserine-
exposure and the rapid release of platelet microvesicles (MV). Platelet activation and MV 
release were complement-dependent and required membrane insertion of C5b-8 but not stable 
lytic pore formation by C5b-9. Full platelet aggregation and activation by ATG also required the 
low-affinity Fc gamma receptor FcγRII. MV release, however, was FcγRII-independent. Platelet 
MV expressed high prothrombinase activity. Moreover, blocking C5 inhibited ATG-induced 
thrombin generation in platelet rich plasma. In 19 hematopoietic stem cell and kidney transplant 
patients, ATG treatment resulted in thrombopenia and increased plasma levels of d-dimer and 
thrombin-anti-thrombin-complexes. Flow cytometric analysis of complement fragments on 
platelet MV in patient plasma confirmed dose-dependent complement activation by ATG. 
However, the rapid rise in MV numbers observed in vitro was not seen during ATG treatment. In 
vitro experiments suggested that this was due to adherence of C3b-tagged MV to red blood 
cells via complement receptor CR1. These data suggest a clinically relevant link between 
complement activation and thrombin generation and offer a potential mechanism underlying 
ATG-induced hypercoagulability. 
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 Introduction 
 
Antithymocyte globulins (ATG) have been used successfully since the 1970s for the prevention 
of graft-versus-host disease in allogeneic hematopoietic stem cell transplantation (HSCT) (1) 
and to prevent or treat rejection in solid organ transplantation, most notably of kidney allografts 
(NTX) (2). ATG are polyclonal immunoglobulins generated by immunizing rabbits with human 
thymocytes (Thymoglobulin®) or the human Jurkat T cell line (ATG-Fresenius®). Its 
immunosuppressive effects are predominantly attributed to a profound and long-lasting 
depletion of T cells (3). It has been proposed that T cell depletion by ATG is achieved through 
various mechanisms including activation-induced apoptosis (4) and complement-dependent 
cytotoxicity, the latter being the dominant mechanism in blood (3, 4). 
  
Whereas ATG-treatment is highly effective, it can be complicated by coagulation activation (5-
8). The latter is commonly referred to as “non-overt disseminated intravascular coagulopathy” 
(9), as laboratory evidence reproducibly denotes thrombopenia and elevated plasma markers of 
hypercoagulability during ATG treatment (6, 10), whereas clinically apparent thrombosis or 
bleeding complications occur less frequently (6, 8). The exact mechanisms underlying this 
phenomenon are not yet known. Previous studies have suggested that ATG treatment induces 
a cytokine-mediated release of tissue factor (TF) into the circulation (6). Recently, Langer et al. 
showed that ATG binding to monocytes resulted in rapid complement-dependent TF decryption 
and activation of the extrinsic coagulation pathway (11). An alternative mechanism was 
proposed by Ankersmit et al., who reported that ATG induces platelet aggregation and 
activation via binding to the low affinity Fc gamma receptor FcγRII on platelets (12). Although 
the specific antigenic targets on platelets have not yet been identified, ATG is known to bind to 
platelet surfaces (13). In vitro, complement activation and deposition of the membrane attack 
complex C5b-9 on platelets has been shown to induce platelet activation and the translocation 
of phosphatidylserine (PS) from the inside to the outside of plasma membranes (14). PS can 
serve as a catalytic surface for the assembly of clotting factors into specific complexes. 
Whereas the TF:factor VIIa (FVIIa) complex is required for the initiation of hemostasis, the 
prothrombinase complex FVa:FXa:prothrombin is the major amplification mechanism, ultimately 
resulting in generation of thrombin, which is the critical step in coagulation activation. C5b-9 also 
induces shedding of microvesicles (MV) from the platelet surface (15). These MV display 
significant prothrombinase activity and have been proposed to constitute the principal catalytic 
surface for the prothrombinase complex (15, 16). Platelet MV can be isolated from blood of 
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 healthy individuals (17). They have been found increased in various pathological conditions 
including sickle cell anemia (18), sepsis (19) and hemolytic uremic syndrome (20) and are 
thought to contribute to disease-related hypercoagulability (21). 
On the basis of these findings, we hypothesized that the clinical phenomenon of ATG-induced 
hypercoagulability is a consequence of complement activation on platelets and subsequent 
release of procoagulant MV. To test this hypothesis, we first characterized the effects of ATG-
mediated platelet activation in vitro and then studied platelet MV release during ATG treatment 
in HSCT and NTX patients.  
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 Results 
 
ATG induces aggregation and activation of platelets. We first set out to analyze the effect of 
ATG on platelet function by assessing the ability of ATG to induce aggregation and activation of 
platelets. Using light transmission aggregometry and platelet rich plasma (PRP), ATG alone had 
no effect on platelet aggregation (not shown). When platelets were simultaneously primed with 
low concentrations of ADP (0.75-1.5μM), ATG dose-dependently (10-100 μg/ml) induced strong 
and stable platelet aggregation. ADP alone or in combination with polyclonal rabbit IgG only 
caused a transient agglutination of platelets, indicating an ATG-specific effect (Figure 1A-B). 
Using flow cytometry, we next determined the impact of ATG on platelet activation assessing 
degranulation (surface expression of p-selectin) and exposure of PS (binding of annexin V). 
ATG bound to and dose-dependently activated platelets both in whole blood (Figure 1C,D) and 
PRP (Figure 1F). Platelet activation was ATG-specific as it did not occur in response to 
polyclonal rabbit IgG. Blocking the low affinity Fc receptor FcγRII on platelets using an anti-
CD32 antibody reduced, but did not fully abolish, ATG-induced platelet aggregation (Figure 1E). 
Consistently, incubation of platelets with ATG following FcγRII blockade still caused significant 
platelet activation (Figure 1F). These findings suggested that there was a dose-dependent, 
FcγRII-independent activating effect of ATG on platelets. 
 
 ATG induces the release of platelet microvesicles with prothrombinase activity. We next 
investigated whether platelet activation by ATG resulted in the release of MV. Following 
incubation of whole blood with ATG, platelet MV were isolated by sequential centrifugation and 
characterized as well as counted by flow cytometry. We found a dose-dependent increase of 
CD41+ annexinV+ double-positive platelet MV in response to ATG, which was not observed 
with polyclonal rabbit IgG (Figure 2A-B). Blocking FcγRII on platelets prior to incubation with 
ATG had no effect on the number of MV released (Figure 2C). The surface of ATG-induced 
platelet MV was highly enriched in the coagulation factor FV/Va (Figure 2D), which is part of the 
prothrombinase complex. Consequently, addition of increasing amounts of platelet MV to 
plasma resulted in a dose-dependent activation of thrombin in a chromogenic thrombin assay 
(Figure 2E). 
 
Role of complement in ATG-induced platelet activation and MV release. We next used flow 
cytometry to analyze platelets and platelet MV for surface deposition of complement fragments 
as an indicator of complement activation following ATG binding. Incubation of platelets with 
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 rabbit IgG in the presence of normal human serum (NHS) resulted in deposition of low levels of 
C1q, C4d and C3b, whereas C5b-9 was undetectable. After incubation with ATG, however, 
there was evidence of robust complement activation on platelet membranes (Figure 3A). 
Platelet MV analysis resulted in three major observations (Figure 3A). First, constitutive MV (low 
numbers released in the absence of ATG) weakly bound C1q and C4d, but displayed 
considerable binding of C3b. C5b-9, however, was absent. Second, analysis of ATG-induced 
MV revealed strong ATG-binding and substantial deposition of all complement fragments 
including C5b-9. Third, fluorescence intensity of ATG and C5b-9 was higher on MV than on 
platelets indicating a higher density of these molecules on MV compared to platelets. In 
conjunction with the much smaller surface area of MV compared to platelets, these findings 
indicated a preferential shedding of ATG and C5b-9 from platelets by vesiculation. Moreover, 
these results suggested that vesiculation took place in proximity of the terminal complement 
complex proteins and raised the question whether complement activation was required for this 
platelet response. To test this, we preincubated serum with eculizumab, which blocks cleavage 
and activation of C5. This significantly inhibited the release of MV in response to ATG (Figure 
3B). Blocking membrane insertion of C5b-7 with a monoclonal antibody targeting native C7 was 
equally effective (Figure 3C). Using C8-depleted serum, MV release was completely abolished 
(Figure 3D). In contrast, blocking C9 with a monoclonal antibody that prevents stable lytic pore 
formation by inhibiting incorporation of C9 into the C5b-8 complex (11), had no effect (Figure 
3E). Of note, MV release paralleled PS surface exposure (Figure 3 F-G) and degranulation (not 
shown) of platelets, which was significantly inhibited in the absence of C8 or following blockade 
of C5 or C7. Consistently, blockade of C9 had no effect (Figure 3F). These results indicated that 
ATG-induced platelet activation and MV release required insertion of C5b-8 into the platelet 
membrane but not stable lytic pore formation by C5b-9. 
  
 ATG-induced platelet prothrombinase activity can be inhibited by complement blockade. We 
next asked whether blocking complement-dependent platelet activation would inhibit ATG-
induced prothrombinase activity in PRP. ATG treatment of PRP resulted in rapid generation of 
thrombin in a fluorogenic thrombin assay. We found a shorter lag time and steeper increase of 
the fluorogenic signal following treatment with ATG compared to control IgG (Figure 3H). 
Endogenous thrombin potential (area under the curve), however, was comparable, potentially 
reflecting earlier clotting and subsequent inhibition of complement activation on platelets. 
Importantly, pretreatment of platelets with eculizumab reduced all parameters of thrombin 
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 generation, indicating that complement activation was indeed required for thrombin generation 
and that ATG-induced hypercoagulability can be inhibited by anti-C5 treatment. 
         
ATG cause thrombopenia, hypercoagulability and complement activation in patients. To 
corroborate our in vitro findings, we next analyzed blood from patients receiving ATG either prior 
to HSCT (n=10) or during NTX (n=9). In both patient groups, we found a rapid reduction in 
platelet counts detectable already at the end of the first ATG infusion (Figure 4A). Plasma levels 
of d-dimer and thrombin-anti-thrombin (TAT) complexes were elevated on day 1 compared to 
baseline (Figure 4 B-C). There was a significant correlation between the absolute drop in 
platelets between baseline and day 1 to TAT levels on day 1 (Spearman correlation coefficient 
r=0.70 p=0.002, Figure 4D). Levels of sC5b-9 increased during the course of ATG treatment, 
albeit to a modest degree (Figure 4F). 
 
Kinetics of platelet MV release during ATG treatment. Next, we counted and characterized 
plasma platelet MV by flow cytometry during ATG treatment (Figure 5A). At baseline, there was 
no significant difference in CD41+ annexinV+ double-positive platelet MV counts between 
HSCT and NTX patients and healthy controls (Figure 5B). Of note, the three NTX patients with 
post-operative bleeding (n=2/9) or thrombotic complications (n=1/9) had the highest platelet MV 
counts at baseline (47, 136 and 222x105 MV/ml plasma, respectively, Figure 5B). Contrary to 
what we had hypothesized, we observed a decrease (defined as less than 50% of baseline) 
rather than an increase (defined as doubling) in platelet MV counts 15 min following the start of 
ATG in 50% (9/18) of the patients analyzed. Compared to baseline numbers, MV counts at later 
time points either remained low (HSCT patients) or varied considerably with no clear pattern 
identifiable (NTX patients) (Figure 5C). 
 
Patient platelet MV stain positive for ATG and complement fragments. There was a rapid 
percentual increase in ATG-positive platelet MV that peaked after ATG infusion in both groups 
(Figure 6A). Staining for C4d showed high inter-individual variability without significant changes 
during ATG treatment (Figure 6B). Deposition of C3d and C5b-9 differed between the two 
groups. In NTX patients, deposition of both proteins increased and peaked after ATG infusion 
with a high correlation between these two parameters (Spearman correlation coefficient r=0.67, 
p<0.01). In HSCT patients, no relevant changes in C3d or C5b-9 deposition were observed over 
time and deposition of both proteins was significantly lower compared to NTX patients (Figure 6 
C-D). Complement activation in NTX patients was due to ATG and not related to the surgical 
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 procedure, as platelet MV from a cohort of NTX patients not treated with ATG displayed 
significantly less C5b-9 deposition at a comparable time point (Figure 6E). These findings 
indicated a higher degree of complement activation in NTX compared to HSCT patients, which 
was likely a reflection of the higher dose and infusion speed in the former compared to the 
latter. There was no significant correlation between the magnitude of complement fragment 
deposition at any time during ATG treatment and the plasma markers of hypercoagulability 
tested. 
  
 ATG-opsonized MV adhere to red blood cells in vitro. Next we tried to understand the 
discrepancy between the dose-dependent release of platelet MV in response to ATG in vitro 
and the lack thereof seen in ATG-treated patients. We hypothesized that complement fragment 
deposition on ATG-induced MV facilitated binding to cells carrying complement receptors (CR). 
We focused on red blood cells (RBC) due to their predominance in blood and the well-described 
phenomenon of immune-adherence of C3b-positive immune complexes to RBC via CR1(22, 
23). Following incubation of CFSE-labeled ATG-negative MV with RBC, there was some binding 
of MV to RBC (Figure 7A) consistent with the presence of C3b on ATG-negative MV (Figure 
3A). However, there was a major increase in binding when equal numbers of ATG-positive MV 
were incubated with RBC (Figure 7A). Blocking CR1 on RBC significantly reduced MV binding 
(Figure 7B), suggesting that CR1 indeed mediated this interaction. Taken together, these results 
suggested that plasma platelet MV numbers are under-estimated during ATG treatment due to 
the excess capacity of RBC to bind complement-opsonized MV via CR1.  
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 Discussion 
 
In this study, we describe a mechanism how immunosuppressant therapy with ATG activates 
platelets and establish a link between complement and coagulation activation as a potential 
explanation for the clinically observed phenomenon of ATG-induced hypercoagulability. 
  
One of the major findings of the present study is that both platelet exposure of PS and MV 
shedding in response to ATG were dependent on membrane insertion of the complement 
proteins C5b-8 but that full lytic pore formation by C5b-9 was dispensable. In line with these 
findings, Langer et al. recently demonstrated that ATG-induced PS exposure on THP-1 
monocytes required C5b-7 insertion but not full MAC assembly. The specific role of C8, 
however, was not addressed (11). Integration of C8 into membrane bound C5b-7 causes target 
cell activation by inducing an inward directed calcium flux (24). Sims et al. previously 
demonstrated that platelet vesiculation following membrane assembly of C5b-9 was calcium-
dependent but did not address the specific contribution of C8 versus C9 (15). Our data strongly 
suggest that membrane insertion of C8 is the critical step triggering ATG-induced platelet 
activation and subsequent vesicle release. 
  
Whereas PS is critical in supporting coagulation activation, TF has a major role in initiating it. In 
this regard, it is important to note that Langer et al. recently reported on rapid activation of 
monocyte TF by ATG (11). Whether platelets and platelet MV express TF is highly controversial. 
Some investigators have attributed platelet TF to monocyte-derived MV bound to platelets (21). 
We were not able to induce thrombin generation in PRP by ATG without addition of purified TF 
(unpublished observation). Therefore, it is likely that the mechanism described by Langer et al. 
is critical for initiation of ATG-induced hypercoagulability, whereas the mechanism described 
here is complementary in that it potently amplifies clotting once it has been initiated. 
  
Previous studies have already reported on plasma MV in the context of ATG treatment (10, 25). 
Using flow cytometry, either total (10) or platelet (25) MV were counted before and compared to 
MV counts after several days of ATG treatment. These studies did not find any difference in 
plasma MV numbers. Based on the rapid MV release in response to ATG observed in vitro, we 
studied plasma platelet MV numbers within minutes to hours following the first dose of ATG, 
hypothesizing that this approach would allow for the detection of a temporary rise in platelet MV. 
The unexpected finding of an early decrease rather than increase in MV counts after starting 
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 ATG suggested that in patients, ATG-induced platelet MV are either rapidly cleared from the 
circulation or adhere to circulating cells, these two mechanisms not being mutually 
exclusive(22). MV are cleared within minutes following intravenous injection in mice (26, 27). 
Various uptake mechanisms have been proposed involving PS on MV and the integrin αvβ3 on 
phagocytic cells (27, 28). Alternatively, uptake might involve C3b on MV and its receptor CR1 
on macrophages (29). Moreover, CR1 is known to mediate binding of C3b-tagged immune 
complexes to RBC in the blood stream, which then shuttle these complexes to the monocyte-
macrophage system in spleen and liver for degradation (22, 23). Our results do not rule out 
binding of C3b-opsonized MV to cells other than erythrocytes, e.g. CR1-positive neutrophils (20, 
29). However, given that 95% of CR1 in the circulation can be found on RBC and that clustering 
of CR1 on RBC facilitates target binding (22), it is likely that the mechanism described here is 
relevant for immune adherence of ATG-opsonized MV. Consistent with previous reports (30), 
we observed complement fragment deposition on MV independent of antibody binding. 
Moreover, we found weak but relevant binding of ATG-negative MV to RBC. This suggests that 
immune adherence of MV occurs constitutively and might be a physiological means to maintain 
MV homeostasis. We also observed direct binding of ATG to MV shed constitutively in vitro 
(unpublished observation). Binding of free ATG to preexisting plasma MV and subsequent 
immune adherence to RBC might explain the persistently lower than baseline MV counts 
observed during ATG treatment especially in HSCT patients. Lastly, complement fragment 
deposition on MV in the absence of ATG as well as immune adherence of ATG-opsonized MV 
might explain the lack of correlation between MV counts or phenotype and the serological 
markers of hypercoagulability tested. 
 
Our findings have several potential clinical implications. Blocking FcγRII, as previously 
suggested (12), might be insufficient to prevent ATG-induced hypercoagulability given that NTX 
patients treated with IVIG (whose primary mechanism of action is saturating Fc receptors) 
displayed the same degree of thrombopenia and hypercoagulability compared to HSCT patients 
not treated with IVIG. High baseline platelet MV counts might help identify those patients prone 
to ATG-induced hypercoagulability. Complement blockade during ATG treatment might prevent 
coagulation activation in these patients. Of note, both clinical (31, 32) and experimental (33, 34) 
evidence suggests that T cell depletion by ATG still occurs in the absence of terminal 
complement activation and therefore blocking C5 with eculizumab might be a potential 
therapeutic to limit ATG-induced hypercoagulability.  
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 Taken together, we have identified how ATG activates platelets and how complement activation 
on target cells results in vesicle shedding and hypercoagulability. These findings might not only 
be relevant in the context of ATG treatment but potentially extent to other pathological 
conditions of focal complement activation like thrombotic microangiopathy or antibody-mediated 
allograft rejection. Moreover, CR1-mediated immune-adherence of C3b-coated MV might be a 
general mechanism contributing to the homeostasis of cell-derived MV.  
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 Materials and Methods 
 
Reagents and antibodies. Antithymocyte globulins (ATG-Fresenius®) were from Fresenius 
(Oberdorf, Switzerland), polyclonal rabbit IgG from BioXCell (West Lebanon, USA), anti-C5 
(eculizumab®) from Alexion Pharmaceuticals (Lausanne, Switzerland), anti-C7 (clone A221) 
from Quidel (San Diego, USA), anti-C9 (X197) from Hycult Biotech (Uden, Netherlands) and C8-
depleted serum was from Sigma (Buchs, Switzerland). Murine mAb V237 recognizing human 
FV/Va was a generous gift from Dr. Charles Esmon (OMRF, Oklahoma, USA). Anti-CD32 (FUN-
1) was from Biolegend (San Diego, USA), anti-CR1 (J3D3) from Beckman Coulter (Nyon, 
Switzerland) and CFSE from Molecular Probes (Zug, Switzerland).  
 
Platelet stimulation and MV release in vitro. 1 ml refludan-anticoagulated blood was incubated 
with ATG or rabbit IgG for 30 min at 37°C. Blood was then either used directly or was 
centrifuged twice at 3000xg for 10 min to generate plasma. Plasma was further centrifuged at 
18500xg for 15 min to isolate MV. Alternatively, platelet rich plasma (PRP) was obtained from 
refludan-anticoagulated blood centrifuged 2 min at 750xg. PRP was diluted 1:10 in Ca-free 
Tyrode’s buffer. 0.25 ml of this solution (1x107 platelets) were incubated for 30 min at 37°C with 
ATG and 10% autologous normal human serum (NHS) in a buffer containing 2.5 mM CaCl2. 
Where indicated, PRP and NHS were preincubated with antibodies blocking individual 
complement proteins for 15 min at RT before adding ATG. To study the impact of C8, 
sepharose gel-filtered platelets were incubated with 20% NHS or C8-depleted NHS in the 
presence of ATG. Following washing, platelets were analyzed by flow cytometry. MV were 
isolated by sequentially centrifuging the platelet supernatant (10 min at 1000xg then 15 min at 
18500xg). All donors gave informed consent before the blood draw. 
  
Platelet aggregation. Aggregation of PRP (2.5-3x105 platelets/µl) was assessed photometrically 
using an APACT4004 aggregometer (Labitec, Ahrensburg, Germany). After 60 seconds, ADP 
(0.75-1.5 μM) was added alone or together with varying amounts of ATG or IgG. Aggregation 
was assessed over the next 9 minutes. 
 
Thrombin generation assays. To assess MV prothrombinase activity, equal volumes of MV 
(generated by stimulating platelets with increasing concentrations of ATG or IgG in the presence 
of NHS) were incubated with 25% normal human plasma and the chromogenic substrate 
TH8198 (Pefachrome®, DSM, Basel, Switzerland). After thrombin-mediated cleavage of the 
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 substrate, the amount of p-nitroaniline dihydrochloride formed was determined by kinetic 
measurements of absorbance at 405 nm on a Synergy H1 microplate reader (Biotek, Luzern, 
Switzerland). Thrombin generation in PRP was determined using the calibrated automated 
thrombogram (Thrombinoscope, Stago, Zürich, Switzerland) on a Thermo Fisher fluorometer. 
Briefly, citrated PRP (1x106 platelets/μl) was mixed with 0.1 mg/ml ATG or rabbit IgG and CaCl2 
(10 mM final concentration) for 5 min prior to adding 0.5 pM TF. The fluorogenic substrate 
amino-methyl-coumarin was then added and thrombin generation recorded over time. Where 
indicated, PRP was preincubated with 0.25 μg/ml anti-C5 prior to adding ATG.  
 
Clinical study protocol. Plasma samples were obtained from patients receiving ATG between 
January and December 2013 at Basel University Hospital. Patients undergoing deceased donor 
renal transplantation were given ATG (ATG-Fresenius®, Fresenius, Oberdorf, Switzerland) at 9 
mg/kg or Thymoglobulin® (Genzyme, Naarden, Netherlands) at 1.5 mg/kg body weight, 
respectively, over 4 hours during surgery. All patients had received 500 mg methylprednisolone 
and IVIG (0.4 g/kg body weight) and had been started on mycophenolate-mophetil and 
tacrolimus within 24 hours prior to transplantation. Patients with hematological malignancies 
were given ATG-Fresenius® (5 mg/kg body weight over 6 hours) on day -3 relative to HLA-
identical non-related hematopoietic stem cell transplantation. These patients were 
simultaneously started on various conditioning chemotherapies and had received 100 mg 
methylprednisolone prior to the start of ATG. The study had been approved by the local ethical 
committee and all patients had given written informed consent prior to inclusion in the study. 
Blood was drawn at the following time points relative to the start of the first ATG infusion: prior 
to start (baseline), 15, 30, 120 min, after the infusion and 24h later prior to the second dose of 
ATG (day 1). Platelet counts and coagulation parameters were determined at the central 
laboratory of Basel University Hospital. EDTA- and heparin-plasma were frozen at -80°C within 
two hours of blood drawing following two centrifugations at 3000xg and snap freezing in liquid 
nitrogen. For MV analysis, heparin-plasma was thawed at 37°C, diluted in 0.22 μm filtered 
HBSS+Hepes and centrifuged at 16000xg. The pellet was resuspended in 0.25 ml for flow 
cytometric analysis.  
 
Flow cytometric analysis of platelets and platelet MV. Refludan-anticoagulated whole blood, 
PRP, platelet MV or MV isolated from patient plasma were resuspended in 0.22 μm filtered 
buffers and incubated with annexin V-APC (Immunotools, Forsythe, Germany) and 
fluorescently-tagged antibodies against the following targets as indicated: CD41 (clone HIP8, 
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 BD), CD235a (HI264, BD), CD62P (AK4, Biolegend), polyclonal C1q and C3d (both Dako). C5b-
9 staining was performed using unlabeled mouse anti-C5b-9 (aE11, Dako) followed by anti-
mouse IgG Alexa488 (Invitrogen). Monoclonal anti-C4d (A213, Quidel) was fluorescently 
labeled using the Lightning-Link Rapid Dylight 488 kit (Innova Biosciences). ATG binding was 
revealed using goat anti-rabbit IgG Alexa488 (Invitrogen). Flow cytometry was performed on a 
CyanADP (in vitro experiments) or a Gallios cytometer (patient samples, both Beckman 
Coulter). MV were gated on logarithmic FSC/SSC scale with an arbitrary SSC threshold using 
CyanADP and no threshold on Gallios. The number of specific MV was quantitated using 
Trucount® beads (BD) as follows: (number of beads x % MV of total events (FSC/SSC) x % 
specific population) / % beads). Data were analyzed using FloJo software (version 9.5.2, 
TreeStar, San Jose, USA). 
 
MV adherence to red blood cells. Platelet MV were generated by incubating PRP with 200 µg/ml 
ATG (ATG+ MV) or rabbit IgG (control MV) + 10% NHS as described above. Equal numbers of 
MV were then incubated with 5 µM CFSE for 15 min at 37°C. Following washing, CFSE-positive 
MV were incubated with washed autologous red blood cells (RBC) at a ratio of 100:1 for 15 min. 
Following washing, MV binding to RBC was revealed by flow cytometry. Where indicated, 1x107 
RBC were incubated with 0.1 mg/ml unlabeled anti-CR1 for 15 min. 1/100 of this solution was 
then added to 1x107 CFSE-labeled MV containing 0.1 mg/ml anti-CR1 and incubated for 30 min 
at 37°C. Following washing, binding was assessed flow cytometry. 
 
sC5b-9 ELISA. EDTA plasma samples were analyzed for sC5b-9 using the Microvue® sC5b-9 
Plus ELISA Kit (Quidel, San Diego, USA). 
 
Statistical analysis. Data are presented as mean ± SD. Comparison between groups was done 
using paired or unpaired t-test or one-way ANOVA with Bonferroni’s multiple comparison post 
testing. Analyses were performed using Prism software (version 6; GraphPad Software). 
Significance was set at p < 0.05. 
  
76
 Acknowledgments 
 
D.Z. was supported by Fondation Machaon, Geneva, Switzerland and Wissenschaftsfonds of 
Basel University Hospital, Basel, Switzerland. J.A.S. was supported by the Swiss National 
Science Foundation.  
 
Authorship 
 
A.C. and D.Z. designed and performed experiments and wrote the paper. E.G. and J.J. 
performed experiments. D.T., M.D. and S.S. gave conceptual advice and J.A.S. supervised the 
project.   
77
 References 
 
1. Kumar A, Mhaskar AR, Reljic T, Mhaskar RS, Kharfan-Dabaja MA, Anasetti C, Mohty M, 
and Djulbegovic B. Antithymocyte globulin for acute-graft-versus-host-disease 
prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a 
systematic review. Leukemia. 2012;26(4):582-8. 
2. Brennan DC, Daller JA, Lake KD, Cibrik D, and Del Castillo D. Rabbit antithymocyte 
globulin versus basiliximab in renal transplantation. N Engl J Med. 2006;355(19):1967-
77. 
3. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. 
Leukemia. 2007;21(7):1387-94. 
4. Genestier L, Fournel S, Flacher M, Assossou O, Revillard JP, and Bonnefoy-Berard N. 
Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by 
polyclonal antithymocyte globulins. Blood. 1998;91(7):2360-8. 
5. Pihusch R, Holler E, Muhlbayer D, Gohring P, Stotzer O, Pihusch M, Hiller E, and Kolb 
HJ. The impact of antithymocyte globulin on short-term toxicity after allogeneic stem cell 
transplantation. Bone Marrow Transplant. 2002;30(6):347-54. 
6. Weber M, Kröger N, Langer F, Hansen A, Zabelina T, Eifrig B, Hossfeld DK, and Zander 
AR. Non-overt disseminated intravascular coagulation in patients during treatment with 
antithymocyte globulin for unrelated allogeneic hematopoietic stem cell transplantation. 
Bone marrow transplantation. 2003;31(9):817-22. 
7. Madaio MP, Spiegel JE, and Levey AS. Life-threatening thrombocytopenia complicating 
antithymocyte globulin therapy for acute kidney transplant rejection. Evidence of in situ 
immune complex formation on the platelet surface. Transplantation. 1988;45(3):647-9. 
8. Trivedi HS, Lal SM, Gupta N, and Ross G, Jr. ATGAM associated coagulopathy in renal 
transplant patients: a report of two unusual cases. The International journal of artificial 
organs. 1996;19(8):448-50. 
9. Taylor FB, Jr., Toh CH, Hoots WK, Wada H, Levi M, Scientific Subcommittee on 
Disseminated Intravascular Coagulation of the International Society on T, and 
Haemostasis. Towards definition, clinical and laboratory criteria, and a scoring system 
for disseminated intravascular coagulation. Thromb Haemost. 2001;86(5):1327-30. 
10. Inbal A, Lubetsky A, Shimoni A, Dardik R, Sela BA, Eskaraev R, Levi I, Tov NS, and 
Nagler A. Assessment of the coagulation profile in hemato-oncological patients receiving 
78
 ATG-based conditioning treatment for allogeneic stem cell transplantation. Bone marrow 
transplantation. 2004;34(5):459-63. 
11. Langer F, Spath B, Fischer C, Stolz M, Ayuk FA, Kröger N, Bokemeyer C, and Ruf W. 
Rapid activation of monocyte tissue factor by antithymocyte globulin is dependent on 
complement and protein disulfide isomerase. Blood. 2013;121(12):2324-35. 
12. Ankersmit HJ, Roth GA, Moser B, Zuckermann A, Brunner M, Rosin C, Buchta C, Bielek 
E, Schmid W, Jensen-Jarolim E, et al. CD32-mediated platelet aggregation in vitro by 
anti-thymocyte globulin: implication of therapy-induced in vivo thrombocytopenia. 
American journal of transplantation : official journal of the American Society of 
Transplantation and the American Society of Transplant Surgeons. 2003;3(6):754-9. 
13. Greco B, Bielory L, Stephany D, Hsu SM, Gascon P, Nienhuis A, and Young N. 
Antithymocyte globulin reacts with many normal human cell types. Blood. 
1983;62(5):1047-54. 
14. Wiedmer T, Esmon CT, and Sims PJ. On the mechanism by which complement proteins 
C5b-9 increase platelet prothrombinase activity. J Biol Chem. 1986;261(31):14587-92. 
15. Sims PJ, Faioni EM, Wiedmer T, and Shattil SJ. Complement proteins C5b-9 cause 
release of membrane vesicles from the platelet surface that are enriched in the 
membrane receptor for coagulation factor Va and express prothrombinase activity. The 
Journal of biological chemistry. 1988;263(34):18205-12. 
16. Sinauridze EI, Kireev DA, Popenko NY, Pichugin AV, Panteleev MA, Krymskaya OV, 
and Ataullakhanov FI. Platelet microparticle membranes have 50- to 100-fold higher 
specific procoagulant activity than activated platelets. Thromb Haemost. 2007;97(3):425-
34. 
17. Berckmans RJ, Nieuwland R, Boing AN, Romijn FP, Hack CE, and Sturk A. Cell-derived 
microparticles circulate in healthy humans and support low grade thrombin generation. 
Thromb Haemost. 2001;85(4):639-46. 
18. Nebor D, Romana M, Santiago R, Vachiery N, Picot J, Broquere C, Chaar V, Doumdo L, 
Odievre MH, Benkerrou M, et al. Fetal hemoglobin and hydroxycarbamide moduate both 
plasma concentration and cellular origin of circulating microparticles in sickle cell anemia 
children. Haematologica. 2013;98(6):862-7. 
19. Joop K, Berckmans RJ, Nieuwland R, Berkhout J, Romijn FP, Hack CE, and Sturk A. 
Microparticles from patients with multiple organ dysfunction syndrome and sepsis 
support coagulation through multiple mechanisms. Thromb Haemost. 2001;85(5):810-
20. 
79
 20. Ståhl A-l, Sartz L, and Karpman D. Complement activation on platelet-leukocyte 
complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic 
uremic syndrome. Blood. 2011;117(20):5503-13. 
21. Owens AP, 3rd, and Mackman N. Microparticles in hemostasis and thrombosis. Circ 
Res. 2011;108(10):1284-97. 
22. Schifferli JA, Ng YC, and Peters DK. The role of complement and its receptor in the 
elimination of immune complexes. The New England journal of medicine. 
1986;315(8):488-95. 
23. Horakova E, Gasser O, Sadallah S, Inal JM, Bourgeois G, Ziekau I, Klimkait T, and 
Schifferli JA. Complement mediates the binding of HIV to erythrocytes. J Immunol. 
2004;173(6):4236-41. 
24. Niculescu F, and Rus H. Mechanisms of signal transduction activated by sublytic 
assembly of terminal complement complexes on nucleated cells. Immunologic research. 
2001;24(2):191-9. 
25. Pihusch R, Höhnberg B, Salat C, Pihusch M, Hiller E, and Kolb H-J. Platelet flow 
cytometric findings in patients undergoing conditioning therapy for allogeneic 
hematopoietic stem cell transplantation. Annals of hematology. 2002;81(8):454-61. 
26. Willekens FLA, Werre JM, Kruijt JK, Roerdinkholder-Stoelwinder B, Groenen-Döpp 
YAM, van den Bos AG, Bosman GJCGM, and van Berkel TJC. Liver Kupffer cells rapidly 
remove red blood cell-derived vesicles from the circulation by scavenger receptors. 
Blood. 2005;105(5):2141-5. 
27. Dasgupta SK, Le A, Chavakis T, Rumbaut RE, and Thiagarajan P. Developmental 
endothelial locus-1 (Del-1) mediates clearance of platelet microparticles by the 
endothelium. Circulation. 2012;125(13):1664-72. 
28. Dasgupta SK, Abdel-Monem H, Niravath P, Le A, Bellera RV, Langlois K, Nagata S, 
Rumbaut RE, and Thiagarajan P. Lactadherin and clearance of platelet-derived 
microvesicles. Blood. 2009;113(6):1332-9. 
29. Fearon DT. Identification of the membrane glycoprotein that is the C3b receptor of the 
human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. J Exp 
Med. 1980;152(1):20-30. 
30. Sadallah S, Eken C, Martin PJ, and Schifferli JA. Microparticles (ectosomes) shed by 
stored human platelets downregulate macrophages and modify the development of 
dendritic cells. Journal of immunology (Baltimore, Md : 1950). 2011;186(11):6543-52. 
80
 31. Stegall MD, Diwan T, Raghavaiah S, Cornell LD, Burns J, Dean PG, Cosio FG, Gandhi 
MJ, Kremers W, and Gloor JM. Terminal complement inhibition decreases antibody-
mediated rejection in sensitized renal transplant recipients. American journal of 
transplantation : official journal of the American Society of Transplantation and the 
American Society of Transplant Surgeons. 2011;11(11):2405-13. 
32. Goh BK, Chedid MF, Gloor JM, Raghavaiah S, and Stegall MD. The impact of terminal 
complement blockade on the efficacy of induction with polyclonal rabbit antithymocyte 
globulin in living donor renal allografts. Transpl Immunol. 2012;27(2-3):95-100. 
33. Neff KS, Richards SM, Williams JM, Garman RD, and Ruzek MC. Murine antithymocyte 
globulin T-cell depletion is mediated predominantly by macrophages, but the Fas/FasL 
pathway selectively targets regulatory T cells. Transplantation. 2011;92(5):523-8. 
34. Barth RF, Singla O, and Ward PA. Immunosuppressive effects of anti-lymphocyte serum 
in complement deficient mice. II. Evidence that activity is mediated by C3 independent 
antibodies. J Immunol. 1974;112(2):858-61. 
 
  
81
 Figure legends 
 
Figure 1. ATG induces aggregation and activation of platelets. (A) Platelet rich plasma 
(PRP) was stimulated with low concentrations (0.75-1.5 μM) of ADP and ATG, polyclonal rabbit 
IgG (both 100 μg/ml) or PBS (no Ab) (arrow). (B) PRP was stimulated with ADP and increasing 
concentrations (10-100 μg/ml) of ATG. Aggregation in (A) and (B) was then assessed 
photometrically over nine minutes. (C) Flow cytometric analysis of ATG binding to platelets 
(using a monoclonal anti-rabbit IgG antibody), platelet surface exposure of p-selectin (using a 
monoclonal anti-CD62P antibody) and phosphatidylserine (PS, detected by annexin V) following 
incubation of whole blood with 0.5 mg/ml ATG (red) or control IgG (blue). Platelets were 
identified by forward-sideward-scatter characteristics and positivity for CD41. (D) Platelets in 
whole blood were incubated with increasing concentrations (0.05-0.5 mg/ml) of ATG or 0.5 
mg/ml polyclonal rabbit IgG and analyzed for p-selectin and PS as in (C) (n=3). (E) PRP was 
stimulated with ADP and 100 μg/ml ATG with or without prior incubation with 5 or 25 μg/ml anti-
FcγRII (anti-CD32). Aggregation was assessed as in (A). (F) Platelets were incubated with 
increasing doses of anti-FcγRII (anti-CD32) prior to addition of 100 μg/ml ATG and 10% NHS. 
Platelet activation was analyzed as in (C) (n=5-7). Mean±SD are shown. Representative 
experiments are shown in panels A, B, C, E.  **** P<0.0001. 
 
Figure 2. ATG induces the release of procoagulant microvesicles. (A) Whole blood was 
incubated with 100 μg/ml ATG for 30 min at 37°C. Platelet microvesicles (MV) were isolated by 
sequential centrifugation and characterized and counted by flow cytometry. Forward-sideward-
scatter characteristics compared to 4.2 μm counting beads and surface staining for CD41 and 
PS (using annexin V). (B) Whole blood was incubated with ATG (0.05-0.5 mg/ml) or 0.5 mg/ml 
polyclonal rabbit IgG for 30 min at 37°C prior to isolation of MV (mean±SD, n=3-5). (C) Platelets 
were incubated with increasing doses of anti-FcγRII (anti-CD32) prior to addition of 100 μg/ml 
ATG and 10% NHS for 30 min at 37°C. MV isolation and counting was done as in (A) 
(mean±SD, n=5-7). (D) MV were generated as in (A). Surface expression of factor V/Va was 
revealed by flow cytometry using mAb V237. (E) Platelets were incubated with ATG (0.01-0.25 
mg/ml) or 0.25 mg/ml polyclonal rabbit IgG + 10% NHS for 30 min at 37°C. MV were 
subsequently isolated as in (A). Equal volumes of MV suspensions were then incubated with 
normal human plasma in the presence of TH8198. Thrombin generation was recorded over time 
measuring OD at 405 nm. *P<0.05, ****P<0.0001, n.s. non-significant. Representative 
experiments are shown in panels A,D,E. 
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Figure 3. ATG-induced platelet activation and MV release is dependent on complement 
activation. (A) Platelets were incubated with 100 μg/ml ATG or polyclonal rabbit IgG with 10% 
NHS for 30 min at 37°C. Platelets and isolated platelet MV were then analyzed for binding of 
ATG and surface deposition of complement fragments by flow cytometry using mAbs against 
rabbit IgG, C1q, C4d, C3-fragments and C5b-9. Representative histograms from platelets 
incubated with ATG (red histograms) or IgG (blue histograms) and the respective MV are 
shown. Isotype controls are in gray. (B, C, E) Platelets + 10% NHS were incubated with 0-25 
μg/ml monoclonal antibody against C5 (B), C7 (C) or C9 (E) prior to addition of 100 μg/ml ATG 
for 30 min at 37°C. (D) Gel-filtered platelets were incubated with C8-depleted serum instead of 
NHS. MV isolation and counting in (B-E) was done as in Figure 2A. N=3-4/group. (F, G). 
Platelets were treated as in (B-E) using 10 μg/ml of anti-complement protein antibodies or C8-
depleted serum and analyzed for PS expression by flow cytometry using annexin V (n=4-8). 
Mean+SD is shown. *P<0.05, ***P<0.001, ****P<0.0001. (H) Recalcified PRP was incubated 
with 100 μg/ml ATG or polyclonal IgG for 5 min at RT prior to addition of 0.5 pM TF and 
analyzed for thrombin generation. Alternatively, PRP was incubated with 25 μg/ml anti-C5 mAb 
for 15 min prior to addition of ATG (PRP+aC5 >ATG). Representative experiments are shown in 
panels A and H. 
 
Figure 4. ATG treatment causes thrombopenia, hypercoagulability and complement 
activation in hematopoietic stem cell (HSCT) and kidney (NTX) transplant patients. (A) 
Platelet counts and levels of (B) d-dimer and (C) thrombin-anti-thrombin-complexes (TAT) were 
measured at the indicated time points relative to the first dose of ATG in HSCT (○, n=10) and 
NTX (●, n=9) patients. (D) Correlation between TAT measured on day 1 and drop in platelet 
count between baseline and day 1. (E) Plasma levels of sC5b-9 during ATG treatment in HSCT 
(○, n=10) and NTX (●, n=9) patients determined by ELISA. *<0.05, **P<0.01, n.s. = not 
significant.  
 
Figure 5. Characterization and quantitation of platelet MV during ATG treatment. Total 
plasma MV were isolated as described in methods. (A) Forward/sideward-scatter characteristics 
and surface staining with anti-CD41 and annexinV by flow cytometry. Co-incubation with known 
amounts of beads allowed for quantitation of CD41+ annexinV+ double-positive platelet MV. (B) 
Number of platelet MV prior to the start of ATG infusion in kidney transplant (NTX, n=9) and 
hematopoietic stem cell transplant (HSCT, n=10) patients compared to platelet MV counts in 
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 healthy controls (n=6). (C) Platelet MV counts in NTX and HSCT patients before, during (15, 30 
and 120 minutes after starting ATG) at the end of the first ATG infusion (after) and on day 1. 
n=9 and 10, respectively.  
 
Figure 6. Dynamics of complement fragment deposition on platelet MV during ATG 
treatment. CD41+ annexinV+ double-positive platelet MV were analyzed by flow cytometry for 
surface deposition of ATG (A) and the complement fragments C4d (B), C3d (C) and C5b-9 (D) 
at the indicated time points. For each parameter, a representative histogram is shown (blue) 
including an isotype control (grey histogram). Specificity for ATG was controlled for comparing 
staining with anti-rabbit IgG after the end of ATG treatment (blue) to staining at baseline (red 
histogram). *P<0.05, **P<0.01, ***P<0.001.  
 
Figure 7. ATG-opsonized platelet MV adhere to RBC via complement receptor 1 in vitro. 
(A) 1x105 red blood cells (RBC) were incubated with 1x107 CFSE-labeled ATG-positive (+ATG 
MV) or ATG-negative control (+ctrl MV) platelet MV for 30 min at 37°C. Following washing, 
binding of MV to RBC was assessed measuring CFSE-fluorescence of RBC. RBC without MV 
were used as controls (RBC). (B) RBC were pre-incubated with anti-CR1 prior to incubation with 
CFSE-labeled ATG MV. Binding of MV to RBC was assessed analogous to (A). Representative 
histograms of two independent experiments are shown. 
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 Abstract 
 
Objective: Transfusion of aged blood has been associated with increased morbidity and 
mortality in critically ill patients. During storage, erythrocytes release increasing numbers of 
microvesicles (RBC-MV). We hypothesized that RBC-MV mediate some of the deleterious 
effects of aged blood transfusions.  
 
Approach and Results: We established a murine transfusion model using RBC-MV purified 
from aged mouse erythrocytes. Injection of RBC-MV into healthy mice had no effect. However, 
they aggravated pulmonary leukocyte sequestration and peripheral blood leukopenia induced by 
LPS. LPS-induced proinflammatory cytokines were significantly increased in plasma following 
RBC-MV injection. These effects were not seen in C5aR-deficient mice. In vitro, RBC-MV bound 
C3 fragments after incubation with plasma but failed to bind immunoglobulins, C1q or MBL. 
Preventing thrombin generation inhibited complement activation in vitro and in vivo and 
reversed the proinflammatory effects of RBC-MV in LPS-primed mice. Finally, the RBC-MV-
induced phenotype was recapitulated using phosphatidylserine(PS)-expressing liposomes, 
suggesting that surface expression of PS by RBC-MV was mechanistically involved. 
 
Conclusions: These results point towards a thrombin-dependent mechanism of complement 
activation by RBC-MV independent of the classical, lectin or alternative pathway. Besides 
identifying RBC-MV as potential mediators of transfusion-related morbidity, our findings may be 
relevant for other inflammatory disorders involving intravascular microvesicle release, e.g. sickle 
cell disease or thrombotic microangiopathy. 
 
Abbreviations: RBC-MV, red blood cell-derived microvesicles; PS, phosphatidylserine; LPS, 
lipopolysaccharides. 
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 Introduction 
 
Transfusion of stored erythrocytes is one of the most common in-hospital procedures with 
approximately 14 million transfusions performed in the US every year (1). Up to 40% of 
intensive care patients receive blood products during their hospital stay with a mean of five units 
per patient (2). International blood bank policies allow storage for up to 42 days between 
erythrocyte collection and transfusion. Over the last decades, there has been substantial 
controversy over the question whether an increased storage time of blood products prior to 
transfusion is associated with higher patient morbidity and mortality (3). Whereas some studies 
were negative (4, 5), various other studies found increased overall mortality rates (6-9), a higher 
incidence of post-operative infections (10), renal failure (7) and a higher frequency of clotting 
disorders (11, 12) in patients that received aged compared to those that received fresh blood 
products and identified critically ill individuals, i.e. patients after trauma or cardiac surgery, to be 
the most vulnerable patient population (8, 13). 
During aging, erythrocytes undergo a series of biochemical and physical changes known as the 
“storage lesion”. These changes include lipid and protein oxidation as well as a reduction in 
deformability and osmotic stability, the latter resulting in considerable hemolysis with release of 
free hemoglobin and iron (14). Notably, erythrocytes lose around 20% of hemoglobin and 
membrane surface area over time by the release of microvesicles. Erythrocyte-derived 
microvesicles increase significantly in number during storage (15, 16) and therefore large 
amounts are given to patients at the time of transfusion. Microvesicle release is a coordinate 
and active process coined ectocytosis to account for the fact that these vesicles (ectosomes) 
bud directly from the cell membrane (17). This is contrary to exocytosis that describes the 
release of vesicles (exosomes) following fusion of intracellular multivesicular bodies with the cell 
membrane. Irrespective of their cellular origin, ectosomes harbor phosphatidylserine (PS) in 
their membranes and were shown to have procoagulant activity in vitro with PS serving as a 
platform for thrombin generation (18). Also, human erythrocyte-derived ectosomes (termed 
RBC-MV hereafter) were found to bind complement fragments in vitro (19), suggesting that they 
might be proinflammatory via activation of the complement system. 
Given their potential proinflammatory and procoagulant properties, we established a murine 
transfusion model to test the hypothesis that RBC-MV derived from aged mouse erythrocytes 
mediate pulmonary and extra-pulmonary pathology in mice independent of the two major 
constituents of blood transfusions, i.e. erythrocytes and hemoglobin. 
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 Results 
 
Characterization of red blood cell-derived microvesicles (RBC-MV). We first aimed at 
reproducing the storage lesion of human erythrocytes (RBC) in mice. After 18 days of storage, 
RBC-MV were isolated from the supernatant of stored RBC by sequential centrifugation and 
characterized by flow cytometry. Forward and sideward scatter analysis revealed a 
homogenous population that was >95% positive for Ter119, indicating their RBC origin. 
Consistent with previous reports in humans (20), between 25 and 45% of all microvesicles 
stained positive for AnnexinV, indicating surface expression of phosphatidylserine (Figure 1A). 
Electron microscopy revealed round shaped vesicles with a size approximating 200 nm (Figure 
1B) a finding that was confirmed by nanoparticle tracking analysis (Figure 1C). We next 
compared surface expression of various complement regulatory proteins as well as the integrin-
associated protein CD47 on RBC-MV to that of equally aged RBC. Whereas CD47 and Crry 
were highly expressed on both, DAF and CD59a showed only dim expression on RBC-MV 
compared to RBC, consistent with a specific sorting process of proteins underlying microvesicle 
shedding (Figure 1D). Lastly, we determined both kinetics and magnitude of RBC-MV release 
during storage over time. RBC-MV could be identified at low quantities in the supernatant of 
freshly harvested blood (not shown), but dramatically increased in number after 12 days of 
storage. After 18 days, an average of 1x109 AnnexinV-positive microvesicles could be isolated 
from one milliliter of stored blood (Figure 1E).  
 
Administration of RBC-MV has no effect in healthy mice. Our initial hypothesis was that 
systemic administration of RBC-MV causes acute lung injury in mice analogous to what has 
been reported following injection of anti-MHC-I antibodies (21-23). We injected 5x108 RBC-MV 
intravenously and analyzed lung histology, lung water weight as an indicator of pulmonary 
edema and pulmonary leukocyte infiltration by flow cytometry four hours later. Histological 
analysis of lung sections showed no pathology. Also, total leukocyte as well as neutrophil (PMN) 
counts were similar after injection of RBC-MV compared to PBS-treated controls (Figure 2A-C). 
There were no signs of systemic inflammation as the proinflammatory cytokines IL-6, KC and 
MCP-1 in serum were undetectable (Figure 3). The latter findings also ruled out relevant 
contamination of RBC-MV during storage. These data indicated that RBC-MV cause neither 
lung pathology nor systemic inflammation in healthy mice. 
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 RBC-MV prolong pulmonary neutrophil sequestration and peripheral blood leukopenia in LPS-
primed mice. We next asked whether priming of mice with LPS prior to injection of RBC-MV 
resulted in lung injury analogous to the two-hit models of aged blood supernatant- and antibody-
induced lung injury (21, 22, 24, 25). Two hours following intraperitoneal injection of LPS, RBC-
MV were administered intravenously. Analysis of lung histology four hours later revealed 
increased leukocyte sequestration in small peripheral vessels compared to LPS-primed animals 
that had received PBS instead of RBC-MV (Figure 2A). However, histological changes 
consistent with parenchymal lung injury were not observed in any of the groups. There was an 
increase in lung water in all treated mice compared to PBS-treated controls. Compared to 
controls, lung water was significantly higher only in LPS-primed mice following RBC-MV 
injection (Figure 2B). However, values obtained for all groups were below those reported to 
represent overt pulmonary edema (23). We next quantified and phenotyped pulmonary 
leukocytes by flow cytometry. Consistent with published reports (26), LPS-primed mice showed 
an increase in pulmonary leukocyte counts compared to unprimed mice with the majority of 
these leukocytes being PMN. Administration of RBC-MV at two increasing concentrations 
resulted in a further significant increase in pulmonary PMN sequestration (Figure 2C) four hours 
later. Notably, analysis of peripheral blood leukocytes at that time revealed neutrophilia in LPS-
primed mice, which was significantly reduced after addition of RBC-MV. Kinetic studies revealed 
a pronounced early pulmonary recruitment of PMN in response to LPS. Administration of RBC-
MV resulted in a sustained pulmonary PMN sequestration over the next 2-4 hours in these mice, 
whereas PMN counts decreased more rapidly without infusion of RBC-MV (Figure 2D).  The 
influx of CD11b+ Ly6Chi inflammatory monocytes followed different kinetics. Whereas 
administration of RBC-MV had no impact on their rapid increase following priming with LPS, 
pulmonary monocyte sequestration was prolonged as evidenced by higher numbers four hours 
following RBC-MV injection (Figure 2D). In sum, administration of RBC-MV in LPS-primed mice 
resulted in increased pulmonary PMN sequestration without evidence of invasive lung injury.  
 
RBC-MV amplify systemic inflammation. We next asked whether administration of RBC-MV in 
LPS-primed mice would amplify systemic inflammation. We observed a dose-dependent 
increase in serum levels of the proinflammatory cytokines IL-6, KC and MCP-1 following RBC-
MV injection (Figure 3). 
Role of hemoglobin and surface-expressed phosphatidylserine. Free hemoglobin (Hb) has been 
linked to the complications following transfusion of aged blood(27, 28). Given that RBC-MV 
contain significant amounts of Hb wrapped inside the vesicles during budding from RBC, we 
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 wanted to know whether the phenotype following RBC-MV injection was specific to RBC-MV or 
whether it could also be elicited by the main content of RBC-MV, i.e. Hb. We therefore injected 
two different concentrations of free Hb from lysed aged erythrocytes into LPS-primed mice and 
analyzed both pulmonary phenotype and serum cytokines. The lower dose (1.8 mg) matched 
the Hb concentration in the RBC-MV preparation and was expected to be completely bound by 
haptoglobin in serum (29). The higher dose (18 mg) was hypothesized to exceed the 
haptoglogin-binding capacity and therefore mimic intravascular hemolysis. In LPS-primed mice, 
both doses of free Hb induced pulmonary PMN sequestration comparable to RBC-MV. 
However, whereas administration of RBC-MV resulted in a significant reduction of peripheral 
blood PMN counts, free Hb did not change LPS-induced peripheral blood neutrophilia (Figure 
S1A). At comparable Hb doses, RBC-MV induced significantly higher levels of IL-6, KC and 
MCP-1 compared to free Hb (Figure S1B). Next, we asked whether RBC-MV mediated their 
proinflammatory effects by surface-expressed phosphatidylserine (PS). We injected PS-
containing liposomes in LPS-primed mice. This treatment reproduced both RBC-MV-mediated 
pulmonary PMN sequestration and systemic inflammation (Figure S2A and 2B, respectively), 
which was not the case when LPS-primed mice received phosphatidlycholine (PC)-containing 
control liposomes. In addition, we performed experiments blocking surface PS on RBC-MV by 
preincubating RBC-MV with saturating amounts of AnnexinV prior to intravenous injection in 
LPS-primed mice. This approach did not have a significant effect on pulmonary PMN 
sequestration or peripheral blood neutropenia (Figure S2C). Moreover, IL-6 levels were highly 
variable following blocking with some values being above and some below those measured in 
control animals. Importantly, IL-6 levels were increased following injection of free AnnexinV into 
LPS-primed mice even in the absence of RBC-MV (Figure S2D). Further in vitro experiments 
revealed that incubation of RBC-MV with AnnexinV in the presence of physiologic free calcium 
concentrations (1.25 mmol/l as compared to the commonly used 2.5 mmol/l) resulted in a 
significant reduction of AnnexinV binding (18.8 vs. 51.2%), suggesting that binding of AnnexinV 
to PS might not be stable in vivo. Taken together, these results indicated a specific effect of 
RBC-MV independent of Hb wrapped inside the vesicles or free Hb contaminating the RBC-MV 
preparations. Studies using liposomes further argued against a role for Hb but suggested a role 
for surface-expressed PS in mediating the RBC-MV-induced phenotype in LPS-primed mice. 
   
RBC-MV bind complement fragments in vitro independent of the classical or alternative 
pathway. It has been speculated that some of the negative effects of stored red blood cells 
might relate to the ability of RBC-MV to activate complement via binding of natural antibodies 
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 (30). We therefore investigated classical pathway activation by RBC-MV in vitro. Following 
incubation with plasma, we were unable to detect binding of IgM (Figure 4A) or IgG (not shown) 
on RBC-MV using flow cytometry. Also, there was no binding of MBL (not shown) or C1q 
(Figure 5B). That the latter result was not due to technical reasons became evident when we 
incubated RBC-MV with an antibody against the RBC-MV surface antigen Ter119 prior to 
adding plasma. This time, subsequent incubation with an anti-C1q antibody indicated binding of 
C1q, likely via binding to the anti-Ter119 antibody (Figure 4B).  Notably, we could detect binding 
of C3 fragments using an anti-iC3b antibody (Figure 4C). That this was independent of classical 
pathway activation was further supported by the fact that C3 fragment binding was revealed 
following incubation with both wild-type and Rag-/- plasma, the latter being devoid of antibodies. 
Lastly, chelation of calcium by EGTA prevented C3 fragment binding. This effect could not be 
reversed following addition of magnesium, arguing against involvement of the alternative 
pathway (Figure 4D). 
  
C5aR is critical for the RBC-MV-induced phenotype in vivo. We next assessed plasma levels of 
C5a in our in vivo model and found a rapid rise in C5a following injection of RBC-MV in LPS-
primed mice compared to LPS-treated controls (Figure 4E). To test whether C5a was 
mechanistically involved, we applied our in vivo protocol to Balb/c mice comparing pulmonary 
PMN sequestration and serum cytokines between wild-type mice and mice unable to respond to 
the complement fragment C5a due to a targeted mutation in the gene encoding the C5a 
receptor (C5aR-/-). We observed the same phenotype in Balb/c wild-type compared to B6 mice, 
indicating a strain-independent phenomenon (Figures 4F and G). Strikingly, we found that both 
the RBC-MV-induced increase in pulmonary PMN sequestration and the increase in 
proinflammatory cytokines were completely abolished in LPS-primed mice in the absence of 
C5aR (Figures 4F and G) suggesting that the presence of C5aR is critical for the 
proinflammatory effects mediated by RBC-MV in vivo. 
 
Inhibition of thrombin prevents complement activation in vitro and in vivo and reverses the RBC-
MV-induced proinflammatory phenotype in LPS-primed mice. Microvesicles from platelets but 
also erythrocytes were shown to have procoagulant properties in vitro with surface expression 
of phosphatidylserine serving as a platform for thrombin generation (18). Moreover, thrombin 
can function both as a C5 and C3 convertase (31-33) and therefore can activate complement 
independent of the classical or alternative pathway. Consistent with these studies, C3 fragment 
binding following incubation of RBC-MV with plasma in vitro could be completely prevented 
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 when plasma was used from mice anticoagulated with either heparin (not shown) or refludan, a 
specific thrombin inhibitor (Figure 5A). As mentioned earlier, binding of C3 fragments to RBC-
MV was also inhibited in the presence of EGTA (Figure 4D). Given the effect of thrombin-
inhibition on C3 fragment binding, this finding was consistent with calcium being a necessary 
cofactor for thrombin activation. In vivo, injection of RBC-MV resulted in increased serum levels 
of thrombin compared to LPS-treated controls (Figure 5C). Refludan prevented RBC-MV-
induced pulmonary PMN sequestration (Figure 5D), reversed peripheral blood neutropenia (not 
shown) and abolished RBC-MV-induced pro-inflammatory cytokines, most notably IL-6 (Figure 
5E). Importantly, refludan also reduced plasma levels of C5a, directly linking thrombin 
generation to complement activation (Figure 5B).  
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 Discussion 
 
In this study we established a murine transfusion model to ask whether RBC-MV derived from 
the supernatant of aged erythrocytes have proinflammatory properties when injected 
intravenously into mice. We found that infusion of RBC-MV into healthy mice did not result in 
any pathology. When we extended our studies to LPS-primed mice (mimicking the clinical 
condition of sepsis), we found that under inflammatory conditions, RBC-MV amplified both 
pulmonary neutrophil sequestration and peripheral blood neutropenia and induced higher serum 
levels of proinflammatory cytokines. Mechanistic in vitro and in vivo studies revealed that these 
effects were due to activation of both the complement and the coagulation system. RBC-MV 
induced thrombin-dependent complement activation in vitro and in vivo. Moreover, RBC-MV lost 
their proinflammatory effects in mice unresponsive to the anaphylatoxin C5a and in mice that 
had received the specific thrombin-inhibitor refludan. Studies using liposomes suggested that 
the proinflammatory effects of RBC-MV involve surface expression of PS. Taken together, these 
findings suggest that thrombin can function as a C3 and/or C5 convertase in vivo independent 
of the classical, lectin or alternative complement pathway. 
 
The impetus for this work was the clinical observation that transfusion of aged erythrocytes is 
associated with increased morbidity and mortality in the critically ill, the pathophysiology and 
triggering factors of this phenomenon still being incompletely understood. The results of our 
study are in accordance with several clinical observations. First, aged blood is more harmful in 
critically ill patients compared to healthy individuals, consistent with the observation that RBC-
MV in our model were only harmful in endotoxemic mice whereas healthy mice withstood the 
harmful effects. Second, studies exploring the pathophysiology of anti-HLA antibody-induced 
TRALI (21-23, 34) do not explain why aged blood carries a higher risk of adverse reactions than 
younger blood, given that the amount of antibody in the transfusion bags is not expected to 
change over time. Moreover, these studies do not explain the non-pulmonary complications 
observed in these patients, notably higher rates of multi-organ failure, infections or 
thromboembolic complications (10, 11, 13). The findings presented here offer a possible 
antibody-independent mechanism of transfusion-related pathology. 
 
For the generation of mouse RBC-MV, we aimed at mimicking human RBC purification and 
storage conditions. However, several factors in our protocol differed from human blood banking 
conditions. This included dextran sedimentation for RBC enrichment and MV purification from 
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 RBC aged longer than what is thought to be equivalent to the human maximum storage time of 
42 days (35). These differences might impact both quality and quantity of mouse RBC-MV. 
Although these differences should not preclude the mechanistic findings of our manuscript, a 
direct translation of our findings to human RBC transfusions warrants caution. 
  
Previous animal studies have already suggested that the supernatant of aged erythrocytes can 
mediate transfusion-related complications (24, 25, 36). Hod et al. recently found free iron 
released from damaged stored RBC to amplify LPS-induced inflammation in a murine 
transfusion model (37). Despite differences in RBC purification and storage conditions between 
our study and the work by Hod and coworkers (35, 37), several findings are consistent. First, the 
amount of stored RBC we used to prepare RBC-MV was comparable to that used by Hod et al. 
for injection of stored RBC supernatants or hemolysates. Second, in the absence of LPS-
priming, neither RBC-MV in our study nor the supernatant (containing RBC-MV) or hemolysate 
of stored RBC used by Hod et al. induced inflammation. These results also support that our 
method to generate RBC-MV did not result in a more proinflammatory effect per se. In the 
presence of LPS-priming, infusion of free hemoglobin from aged erythrocytes (likely containing 
iron) did amplify pulmonary PMN sequestration and resulted in an increase in proinflammatory 
cytokines in our model. However, when equal doses of hemoglobin were infused, the 
proinflammatory effects of RBC-MV were significantly more pronounced. Together with the data 
obtained using PS-positive liposomes (that lack hemoglobin), these results suggested that there 
is a hemoglobin-independent proinflammatory effect of RBC-MV, likely via surface expression of 
PS. It is important to note, however, that the evidence using PS-positive liposomes is 
associative. To test for causality, we performed blocking experiments preincubating RBC-MV 
with AnnexinV prior to intravenous injection and found no significant effect on pulmonary 
phenotype and proinflammatory cytokines (Figures IIC-D). Given that injection of AnnexinV in 
LPS-primed mice increased inflammation in the absence of RBC-MV and considering that 
blocking surface PS with AnnexinV might not be stable in vivo, the results from these 
experiments do not allow a final conclusion on the role of PS on RBC-MV in our model. Further 
experiments will have to be done to establish causality. 
  
A crosstalk between the complement and the coagulation system has long been suggested, 
although in vivo evidence is limited. In vitro studies found complement activation products, i.e. 
C3a and C5a, following incubation of serum with clotting factors, notably thrombin (32, 33). 
Recently, Huber-Lang et al. found evidence for thrombin-mediated cleavage of C5 in a mouse 
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 model of immune-complex mediated lung injury (31), linking coagulation to complement 
activation and systemic inflammation in vivo. The procoagulant properties of erythrocyte- and 
platelet-derived microvesicles are well described in the literature and are mainly based on solid-
phase in vitro assays of thrombin generation (18, 38). As in our model, the specific thrombin 
inhibitor refludan was able to prevent both RBC-MV-induced complement activation in vitro 
(assessed by binding of C3 fragments to RBC-MV) and in vivo (evidenced by reduced C5a 
levels in the presence of refludan), our findings support the concept of thrombin-induced 
complement activation. 
 
Outside the context of RBC transfusions, various other diseases like thrombotic 
microangiopathy (TMA) and sickle cell anemia are characterized by hypercoagulability (39), 
systemic complement activation (40) and increased blood levels of microparticles (41-43). Stahl 
et al. recently reported the presence of complement fragments on platelet and monocyte-
derived microparticles in patients with shigatoxin-induced hemolytic uremic syndrome, a form of 
TMA (42)., suggesting a pathogenetic role of microvesicles in these conditions. 
 
Taken together, we have identified RBC-MV to mediate transfusion-related pathology by 
thrombin-dependent activation of the complement system in a mouse transfusion model. These 
findings might not only be relevant for RBC storage and transfusion allocation strategies but 
describe a proinflammatory amplification loop with potential relevance for other conditions 
characterized by intravascular microvesicle release. 
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 Materials and Methods 
 
Mice. C57BL/6 (B6), Balb/c and B6 Rag-/- mice were bred at the institution’s animal facility or 
purchased from Charles River (Sulzfeld, Germany). C.129S4(B6)-C5ar1tm1Cge/J (C5aR-/-) on a 
Balb/c background were from the Jackson Laboratories (Bar Harbor, USA). All mice were 
housed in a specific pathogen-free environment and were used between 7 and 12 weeks of 
age. Animal care and experimentation were performed in accordance with national guidelines 
(Federal Veterinary Office) and had been approved by the local government authorities. 
 
Reagents and monoclonal antibodies. Fluorochrome-tagged mAbs against CD11b (clone 
M1/70), CD45 (30-F11), CD47 (miap301), CD59a (mCD59.3), Ly6C (AL-21), Ly6G (1A8), 
Ter119 (Ly-76), DAF (RIKO-3), Crry (512), IgG (Poly4053), IgM (RMM-1) and purified anti-
CD16/32 (2.4G2) were from Biolegend (San Diego, USA), eBioscience (Vienna, Austria) or BD 
Pharmingen (Allschwil, Switzerland). Anti-iC3b (3.26) and anti-MBL-C (8G6) were from Hycult 
Biotech (Uden, the Netherlands). FITC-conjugated anti-C1q (RmC7H8) was from Cedarlane 
(Burlington, Canada), AnnexinV-APC from Immunotools (Friesoyte, Germany) and 7-AAD from 
Invitrogen (Zug, Switzerland). 
 
Generation and analysis of red blood cell-derived microvesicles (RBC-MV). Mouse RBC-MV 
were generated by aging. Briefly, blood was obtained by cardiac puncture following sacrifice. 
Erythrocytes (RBC) were purified by dextran sedimentation. RBC were stored between 16 and 
18 days at a ratio of 2:1 in the human erythrocyte-storage solution PAGGSM at 4˚C in 
polystyrene tubes (BD). Storage time was chosen empirically to maximize yield of RBC-MV and 
simultaneously minimize concurrent hemolysis. Preliminary experiments had shown significant 
hemolysis (hematocrit < 75% from baseline) in samples stored for longer than 18 days. 
Following storage, supernatants were diluted with PBS and sequentially centrifuged at 250g, 
1210g and 13000g. The final pellet containing RBC-MV was diluted in PBS, stored at 4˚C and 
used within 24 hours. RBC-MV were analyzed by flow cytometry in 0.22 µm-filtered buffers. 
Trucount beads (BD) were used for quantitation. RBC-MV were gated on logarithmic FSC/SSC 
with an arbitrary threshold set on SSC. RBC-MV were further identified as double positive for 
Ter119 and AnnexinV. The number of AnnexinV-positive RBC-MV/ml was calculated as follows: 
(number of Trucount beads x % RBC-MV of total events (FSC/SSC) x % AnnexinV+ of total 
Ter119+) / % Trucount beads. Flow cytometry was performed using a CyanADP cytometer 
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 (Beckman Coulter, Nyon, Switzerland). Data were analyzed using FlowJo Software (TreeStar, 
San Jose, USA). 
 
Generation of liposomes. Unilamellar liposomes, composed of either L-α-phosphatidylcholine 
(PC) alone or PC together with equimolar concentrations of L-α-phosphaditylserine (PSPC, both 
Avanti Polar Lipids, Alabaster, USA) were prepared according to the repeated freeze–thawing 
method and extruded using nucleopore polycarbonate filters (VWR, San Diego, USA) (44). Final 
liposome concentration was 16 mM as measured by a standard phosphate assay. Liposome 
diameter was approximately 200 nm as determined by electron microscopy. 
 
Two-hit experimental protocol. Mice were primed with an intraperitoneal (i.p.) injection of 
Lipopolysaccharides (LPS from Escherichia coli 055:B5 used at 1 mg/kg, Cat. Nr. L2880, 
Sigma, Buchs, Switzerland) followed two hours later by intravenous (i.v.) injection of 5x108 or 
1x109 RBC-MV in a total volume of 200µl PBS via the tail vain. At the indicated times, mice 
were sacrificed with thiopental and organs were harvested. Where indicated, LPS-primed mice 
received 200µl of hemoglobin (Hb) at 9 mg/ml or 90 mg/ml i.v. prepared from stored 
erythrocytes instead of RBC-MV. Hb was obtained by freeze-thawing 18 day-old RBC followed 
by centrifugation at 13000g for 1 hour. Supernatants were analyzed for Hb concentration 
measuring absorbance at 405 nm with known concentrations of human Hb (Sigma) as standard. 
Hb content of RBC-MV was determined accordingly. Alternatively, LPS-primed mice received 
equimolar amounts of PC- or PSPC-liposomes i.v. instead of RBC-MV. Where indicated, the 
specific thrombin inhibitor refludan (Celgene, Boudry, Switzerland)) was given i.p. at 2 mg/kg 15 
min prior to and again two and four hours following injection of LPS, respectively.  
 
Electron microscopy. RBC-MV were fixed in 1% glutaraldehyde and adsorbed to parlodion-
coated copper grids. After washing, samples were stained with 2% uranylacetate and analyzed 
using a Philips Morgani 268D transmission electron microscope operated at 80 kV. 
 
Lung histology. Lungs were fixed in 4% paraformaldehyde and embedded in paraffin. 10 µm 
sections were stained with H&E and analyzed on an Olympus BX61 microscope.  
 
Determination of lung water. Left lungs were removed intact, weighed and dried for > 24 hours. 
Following drying, lungs were weighed again. The percentage of lung weight accounted for by 
water was determined as follows: ((pre- minus post-drying weight)/ pre-drying weight) x100. 
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 Analysis of blood and tissue leukocytes. Peripheral blood was obtained by cardiac puncture. To 
obtain lung-infiltrating leukocytes, right lungs were excised without prior perfusion and digested 
for 30 min at 37°C in RPMI-2.5% FCS + 2 mg/ml Collagenase IV + 0.1 mg/ml DNAse I (both 
Sigma). RBC were removed by hypotonic lysis. Blood leukocytes were counted using 
GLASSTIC® slides (Hycor, USA), the total cell number of the pulmonary homogenate was 
counted with an automated cell counter (Beckman Coulter). Pulmonary neutrophil numbers 
were calculated by multiplying the total cell number of the right lung homogenate by % CD45+ 
CD11b+ Ly6C+ Ly6G+ cells following exclusion of doublets and dead (7-AAD+) cells as 
determined by flow cytometry. Pulmonary monocyte numbers were calculated accordingly with 
monocytes being CD45+ CD11b+ Ly6Chigh Ly5G-. 
 
ELISA and thrombin assay. Serum concentrations for IL-6, KC and MCP-1 were analyzed by 
ELISA following the manufacturers instructions (IL-6 and MCP-1 BD OptEIA, KC R&D 
Systems). For plasma C5a levels and thrombin activity, blood was drawn into tubes containing 
10 mM EDTA. For C5a, ELISA plates were coated with purified monoclonal mouse C5a-specific 
IgG (5 µg/ml, BD). Following blocking with 10% FCS in PBS, plasma was added. C5a was 
revealed using a biotinylated monoclonal mouse C5a-specific antibody (0.5 µl/ml, BD) and SA-
HRP. Recombinant human C5a (BD) was used as a standard. Thrombin activity was 
determined using fresh plasma and TH8198 (Pefachrome®, DSM, Basel, Switzerland) as 
substrate. After thrombin-mediated cleavage of the substrate, the amount of p-nitroaniline 
dihydrochloride formed was measured by absorbance at 405 nm. The assay was performed in 
the presence of aprotinin (Sigma). Unspecific absorbance was corrected for by subtracting 
absorbance in the absence of TH8198 from absorbance in the presence of TH8198 for each 
individual plasma sample (∆OD).  
 
In vitro complement binding studies. Blood from Rag-/- or wild-type mice was obtained by 
cardiac puncture and immediately put on ice. Plasma was harvested following centrifugation (10 
min, 3000g). Anticoagulated plasma was obtained from mice injected 100µg refludan i.p. 5 min 
prior to cardiac puncture the blood being aspirated into syringes containing 100µg refludan. 5 µl 
RBC-MV were incubated with 10% plasma for 30 min at 37°C. Where indicated, 5 mM EGTA 
with or without 1 mM Mg were added to RBC-MV during incubation. Samples were then washed 
at 13000g for 10 min. To reveal binding of IgG, IgM, C1q or iC3b, RBC-MV were incubated with 
the respective flourochrome-tagged mAbs, washed and analyzed by flow cytometry.  
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 Statistical analysis. All data are presented as mean ± SEM. Depending on data distribution, 
comparisons between treatment groups were performed using one-way ANOVA with 
Bonferroni’s multiple comparison post-testing or using a two-tailed Mann-Whitney U test as 
indicated (Prism; GraphPad Software). Significance was set at p < 0.05. 
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 Figure legends 
 
Figure 1. Characterization of red blood cell-derived microvesicles (RBC-MV). Flow 
cytometric analysis of MV after 18 days of storage (A, D). Forward/sideward-scatter 
characteristics compared to 4.2 µm control beads (*) and surface staining for Ter119 and 
Annexin V (A). Differential surface expression of the indicated molecules on RBC-MV compared 
to red blood cells (RBC) both aged for 18 days (D). Transmission electron microscopy of RBC-
MV reveals round shaped vesicles with a size of around 200 nm. Left size bar 1 µm, right size 
bar 200 nm (B). Nanoparticle Tracking Analysis (NTA) of RBC-MV reveals a homogenous 
population with a mean diameter of 200 nm (C). Kinetics of RBC-MV release during storage. 
Data are mean±SEM from 3-8 independent experiments per time point (E). 
 
Figure 2. Systemic administration of RBC-MV amplifies pulmonary neutrophil 
sequestration and peripheral blood leukopenia in LPS-primed mice. B6 mice were primed 
with an i.p. injection of LPS followed by the i.v. injection of 5x108 or 1x109 RBC-MV (LPS+RBC-
MV) two hours later. Alternatively, mice were given LPS i.p. followed by PBS i.v. (LPS). Control 
groups received PBS instead of LPS for priming followed by 5x108 RBC-MV i.v. (RBC-MV) or 
were given PBS i.p. and i.v. (PBS). 4 hours later, lungs were harvested and lung sections 
stained by H&E. Magnification 100 x, inset 600 x. Pictures are representative of at least four 
mice analyzed per group (A). % water weight of lungs of the indicated groups determined as 
outlined in the methods sections. n=3 (PBS, RBC-MV only), 12 (LPS) and 15 (LPS+RBC-MV) 
pooled from several independent experiments (B). Accumulation of CD45+ leukocytes and 
CD11b+ Ly6Cint Ly6G+ neutrophils (PMN) in right lungs as well as peripheral blood leukocyte 
and PMN counts of the indicated groups as determined by flow cytometry. n=4-6/group (lung) 
and 5-7/group (blood) pooled from two representative experiments (C). Kinetics of pulmonary 
CD45+ leukocyte, PMN, and CD11b+ Ly6Chi Ly6Gneg inflammatory monocyte sequestration in 
LPS vs. LPS+5x108 RBC-MV treated mice. N=4-6/group and time point (D). * P < 0.05 using 
one-way ANOVA and Bonferroni’s post-test. Mean±SEM is shown.  
 
Figure 3. Dose-dependent amplification of LPS-induced systemic inflammation by RBC-
MV. Serum levels of IL-6, KC and MCP-1 four hours after i.v. injection of PBS or RBC-MV in 
unprimed (PBS and RBC-MV, respectively) or LPS-primed B6 mice (LPS, LPS+5x108 RBC-MV, 
LPS+1x109 RBC-MV, respectively) as determined by ELISA. N =6-16/group pooled from at least 
112
 three independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001 using a nonparametric 
Mann-Whithey test. Mean±SEM is shown.  
 
Figure 4. Involvement of complement. RBC-MV bind C3 fragments independent of classical 
or alternative pathway activation in vitro. B6 RBC-MV were incubated with wild-type or Rag-/- 
plasma or heat-inactivated (HI) control wild-type serum in vitro. Binding of IgM (A), C1q (B) or 
iC3b fragments (C) was subsequently revealed by flow cytometry following incubation with 
fluorochrome-tagged anti-IgM, anti-C1q or anti-C3b mAbs, respectively. For (B), RBC-MV were 
incubated with an antibody specifically binding to surface glycophorin-A (Ter119) prior to 
incubation with plasma. Binding of C1q was then revealed following incubation with anti-C1q 
mAb (1º α-Ter119, 2º plasma). To test for alternative pathway activation in vitro, RBC-MV were 
incubated with plasma in the presence or absence of EGTA, the latter with (EGTA+Mg) or 
without (EGTA) addition of magnesium. iC3b fragment binding was revealed as in (C) and (D). 
Results are representative of >2 independent experiments (A-D). Increased levels of C5a in 
LPS-primed B6 mice 15 min after i.v. injection of RBC-MV (n=5-6) (E). Amplification of 
pulmonary phenotype and cytokine production by RBC-MV in LPS-primed mice depends on 
complement receptor C5aR. Balb/c wild-type and C5aR-deficient mice were treated as 
described in Figure 2. 4 hours later, pulmonary PMN sequestration (n=7-8) (F) as well as serum 
cytokines (n=7-11) (G) were determined. * P < 0.05, ** P < 0.01, *** P < 0.001 using one-way 
ANOVA and Bonferroni’s post-test (pulmonary PMN counts) or a nonparametric Mann Whitney 
test (cytokines). n.s. = non-significant. Mean±SEM is shown.  
 
Figure 5.  RBC-MV induced effects can be reversed by inhibition of thrombin in vitro and 
in vivo. iC3b binding to RBC-MV in vitro after incubation with plasma can be reversed by 
refludan (A). B6 RBC-MV were incubated with plasma, heat-inactivated control serum or plasma 
from mice that had been anticoagulated with refludan prior to sacrifice. iC3b binding was 
revealed following incubation with an anti-iC3b mAb by flow cytometry (A). Plasma levels of C5a 
and thrombin are reduced in the presence of refludan. LPS-primed B6 mice anticoagulated with 
refludan (+) or not (-) were given 1x109 RBC-MV i.v. 15 min later, plasma was obtained and C5a 
levels (B) and thrombin activity (C) were determined by ELISA and a thrombin assay, 
respectively, as indicated in Methods. Amplification of pulmonary PMN sequestration (D) and 
systemic inflammation (E) in LPS-primed B6 mice 4 hours after injection of RBC-MV can be 
reversed by refludan. N=6-8/group pooled from at least three independent experiments (B-E). * 
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 P < 0.05, ** P < 0.01 using one-way ANOVA and Bonferroni’s post-test (C, D) or a 
nonparametric Mann-Whitney test (B, E). n.s. = not significant. Mean±SEM is shown.  
 
Figure S1. Effect of free hemoglobin on pulmonary phenotype and serum cytokines in 
LPS-primed mice. LPS-primed B6 mice received an i.v. injection of PBS (LPS), 1.8 mg 
hemoglobin (LPS+1.8 mg Hb), 18 mg hemoglobin, or 1x109 RBCMV containing 1.8 mg 
hemoglobin. 4 hours later, pulmonary and peripheral blood PMN counts (A) as well as serum 
cytokines (B) were determined. N=5-6/group pooled from >2 independent experiments each. * P 
< 0.05, ** P < 0.01 using one-way ANOVA and Bonferroni’s post-test (A). N=5-7/group pooled 
from at least three independent experiments. * P < 0.05, ** P < 0.01 using a nonparametric 
Mann Whitney test (B). n.s. = non-significant. Mean±SEM is shown. 
 
Figure S2. The RBC-MV-induced effects can be mimicked by phosphatidylserine-positive 
liposomes. RBC-MV-induced pulmonary phenotype (A) and amplification of proinflammatory 
cytokines (B) in LPS-primed B6 mice can be mimicked by i.v. injection of liposomes containing 
phosphatidylcholine (PC) and phosphatidylserine (PS) at a 1:1 ratio (L+PSPC). Injection of 
PSPC in the absence of LPS (PSPC) or control PC-liposomes in LPS-primed mice (L+PC) had 
no effect. N=7-9/group from at least three independent experiments (A-B). Blocking of PS on 
RBC-MV by preincubation with saturating amounts of AnnexinV prior to i.v. injection in LPS-
primed mice does not reverse the RBC-MV-induced pulmonary phenotype (C) and results in 
highly variable serum levels of IL-6 (D). N=3-5/group from two independent experiments (C-D). * 
P < 0.05, ** P < 0.01 using one-way ANOVA and Bonferroni’s post-test (A) or a nonparametric 
Mann-Whitney test (B). n.s. = not significant. Mean±SEM is shown. 
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Critical points and Future perspectives 
 
PMN-Ecto 
 
In our MSU peritonitis model we could demonstrate that PMN-Ecto actively resolve 
inflammasome mediated inflammation by engaging the PS-MerTK axis. PMN-Ecto were 
released early on by infiltrating PMN and render cells unresponsive to pro-inflammatory stimuli. 
There are, however, several aspects of the MSU peritonitis model and PMN-Ecto mediated 
resolution that remain un-resolved. 
 
Various stimuli have been suggested to induce PMN-Ecto release. These stimuli include fMLP, 
C5a, C5b-9 deposition, Ca-ionophores and PMA (1-3). Although these stimuli are structurally 
diverse and activate different signaling pathways, all share the ability to induce rapid Ca2+ influx 
(3-8). The mechanism triggering Ecto release therefore most likely relies on changes in 
intracellular Ca2+ concentrations. Ca2+ influx or the release of Ca2+ from intracellular stores is a 
feature in many signaling cascades, making Ecto release a general phenomena of cell 
activation, rather than a specific process linked to a particular stimulus or signaling cascade. 
Which stimulus is the most relevant depends on the circumstance. In gout, C5a is likely the 
most potent trigger for neutrophil vesiculation.  
 
Among the various mechanism suggested to resolve gouty inflammation, some may apply to 
PMN-Ecto and foster their ability to inhibit IL-1β release. A group of plasma proteins called 
Annexins bind to PS expressing surfaces.  Annexin A1 (AnA1) was shown to bind to PMN-Ecto 
and hinder neutrophil recruitment in response to IL-1β in an murine air pouch model (9). AnA1 
act by inhibiting phospholipase A2, which in turn is responsible for the synthesis of pro-
inflammatory lipid mediators derived from arachidonic acid (prostanoids and leukotriens). We 
could confirm low levels of AnA1 on PMN-Ecto isolated from gout exudates (Gout-MV). 
Interestingly, the same group reported that PMN-Ecto induce the synthesis of anti-inflammatory 
resolvins (RV1-2, RVE2) by macrophages (10). Resolvins are distal product of phospholipase 
A2 metabolites. It is not yet clear whether PMN-Ecto carry AnA1 and if so, how can they induce 
they synthesis resolvins and inhibit phospholipase A2 at the same time. This conflict was not 
discussed by the group.   
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There are various receptors that have the capacity to recognize PS. These include Tim4, BAI1, 
Stabilin 2, scavenger receptors (CD36, SRA-1), αν integrins and TAM receptors (of which Axl 
and Mer are expressed by immune cells). By using the MerTK-/- we could confirm the 
involvement of TAM receptors in the biological effect of PMN-Ecto. Since the loss of MerTK 
alone was sufficient to cancel the effect of PMN-Ecto, the contribution of Axl is unlikely. The use 
of an Axl-/- would elucidate the relative contribution of each TAM receptor. Although we saw 
MerTK-dependent changes in SOCS1 and 3 expression, the evidence for SOCS1/3 involvement 
remains associative.  
 
PMN-Ecto have the tendency to recruit enzymes from azurophilic (myeloperoxidase, 
proteinase3 and neutrophil elastase) and specific (matrix metalloproteinase-9) granules once 
they are released during neutrophil activation (1). This has several important biological 
implications. PMN-Ecto induce the release of pre-stored TGFβ, but do not initiate its de novo 
synthesis. The mechanism of TGFβ release by PMN-Ecto is poorly understood. Matrix 
metalloproteinase-9 (MMP-9) and neutrophil elastase (NE) have broad substrate specificities 
and are known to cleave latent TGFβ (11). Specifically MMP-9 targets the protease-sensitive 
hinge region of LAP. Once LAP is cleaved TGFβ is released. We could demonstrate that the 
release of TGFβ requires phagocytosis of PMN-Ecto and is in part dependent on MMP-9 and 
NE. NE adsorbed on PMN-Ecto induce the release TGFβ from macrophages much faster than 
free NE. This was arguably due to the fact that the uptake of free NE is unspecific and relies on 
macro-pinocytosis, whereas the clearance of NE on PMN-Ecto is incentivized by PS. In this 
respect, PMN-Ecto function as an effective delivery mechanism for MMP-9 and NE. 
 
In our model TGFβ was dispensable in the PMN-Ecto mediated resolution of acute gout. TGFβ 
was non-essential on 3 counts. Firstly, In the MerTK-/- mice PMN-Ecto failed to achieve 
suppression despite the significant release of TGFβ. Secondly, PMN-Ecto suppression was not 
antagonized by TGFβ blocking. Thirdly, recombinant active mouse TGFβ on its own did not 
suppress inflammation when given instead of PMN-Ecto. Interestingly TGFβ was anti-
inflammatory in vitro. In vitro, recombinant mouse TGFβ inhibited inflammasome priming by 
specifically suppressing the upregulation of NALP3, but did not inhibit pro-IL-1β production. 
TGFβ therefore limits inflammasome activation in macrophages by maintaining their high 
activation threshold for inflammasome stimuli. This may not be the limiting factor in the acute 
phase of gout, but may control the recurrence of subsequent attacks. 
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These findings are contrary to some of the previously published studies. The conclusion that 
TGFβ plays a role in gout is largely based on two studies that pre-date the discovery of the 
inflammasome. In one of the studies TGFβ was shown to be anti-inflammatory in an MSU rat air 
pouch model, where extraneous TGFβ suppressed cell influx (12). In the other in vitro study 
MSU treated human macrophages released TGFβ, which suppressed endothelial cell and 
monocyte activation (13). We could not confirm the in vitro findings that macrophages release 
TGFβ when stimulated by MSU, but in accordance with the study, TGFβ impaired macrophage 
and monocyte response to LPS.    
 
PMN-Ecto recruit myeloperoxidase (MPO) and proteinase 3 (PR3) to their surface (1). Both of 
these antigens are target antigens for autoimmune diseases defined by the presence of anti-
neutrophil cytoplasmic antibodies (ANCA). ANCA antibodies against MPO (pANCA) and PR3 
(cANCA) cause small vessel inflammation, a vasculitis,  affecting the lungs and kidney. What 
initiates ANCA vasculitis is not yet understood, but it is hypothesized that patients with a 
predisposition to autoimmune disease (impaired apoptotic cell clearance) lose tolerance against 
MPO or PR3 during an infection. In particular Staphylococcus aureus carriers infected by Gram-
negative bacteria contribute to induction and persistence of ANCA-associated vasculitis (14). 
Neutrophils are one of the first cell to respond and accumulate at the site of infection. They 
infiltrate in great numbers and typically have short life spans in the course of an immune 
response dying off by an apoptotic or necrotic cell death. While apoptotic cells tolerize the 
immune system to self-antigens, they remain apoptotic only for a short time frame and if not 
cleared undergo secondary necrosis. The potential for anti-inflammatory effect of apoptotic cells 
is therefore limited. In patients with defects in apoptotic clearance this mechanism of ensuring 
peripheral tolerance is less effective. PMN-Ecto generated during neutrophil activation on the 
other hand carry all the abilities of apoptotic cells with respect to their anti-inflammatory effects, 
but are released earlier and do not undergo secondary necrosis. It is plausible to hypothesize 
that recruitment of MPO and PR3 from fluid phase onto PMN-Ecto and the combined effect of 
PS and TGFβ may represent a mechanism for maintain tolerance for self-antigens susceptible 
to an auto-immune response. This hypothesis could be tested on an established model for 
pANCA vasculitis based immunization with MPO and allow us to establish PMN-Ecto release as 
means of maintaining peripheral tolerance .   
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PLT-Ecto 
 
In our in vitro model, ATG recognized platelets and in the presence of serum induced platelet 
activation and release of pro-coagulant PLT-Ecto. Platelet activation and PLT-Ecto release 
relied on classical complement pathway activation and required C5b-7 insertion. In 
hematopoietic stem cell (HSCT) and kidney transplant (NTX) patients, ATG treatment brought 
about a state of heightened coagulation (d-dimer, TAT) and complement activation (soluble 
C5b-9). Although ATG induced the release of PLT-Ecto in vitro, PLT-Ecto count isolated from 
HSCT and NTX patients declined after ATG treatment due to opsonization and adsorption of 
PLT-Ecto to CR1 on erythrocytes. 
 
Given that this was a translational project, the aim was not only to explain clotting (sub-clinical 
DIC) and inflammatory (SIRS, cytokine storm) complication during ATG therapy, but also 
suggest potential targets for prophylaxis. At present ATG pre-medication comprises of 
glucocorticoids (prednisone), anti-histamines, NSAID (acetaminophen) and anti-coagulants 
(heparin). The addition of eculizumab (anti-C5 depleting antibody) inhibited vesicle release, 
platelet activation and consequently pro-thrombinase activity in response to ATG in vitro and 
could ameliorate adverse effects of ATG therapy. 
 
The shedding of C5b-9 complexes in the form of vesicles seems to be a generalized 
mechanism for evading complement mediated lysis. Vesiculation by endothelial cells may 
explain the phenomenon of accommodation in ABO-incompatible NTX, where kidney grafts do 
not undergo antibody mediated rejection despite the presence anti-ABO antibodies. To make 
ABO incompatible NTX possible and avoid hyper-acute rejection, recipients undergo 
plasmapharesis and  both donor and recipient receive B-cell depleting antibodies (rituximab). 
Once anti-ABO antibody titers drop, the NTX can take place. Over the period of 3 months, 
however, recipient anti-ABO antibodies gradually return, but do not cause antibody mediated 
rejection. Kidney grafts undergo the so called process of accommodation formally defined as 
the deposition of C4d, but the absence of late complement fragments (C5b-9) on the graft (15). 
Hypothetically the shedding of C5b-9 complexes by graft endothelial cells during the gradual 
rise of anti-ABO antibodies and subsequent sub-lytic complement attack may explain the 
mechanism underlying graft accommodation. Alternatively, during antibody mediated rejection, 
the release of pro-coagulant endothelial MVs may accelerate thrombotic microangiopathy and 
further compromise graft microcirculation (16).   
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RBC-Ecto 
 
In our murine transfusion model the injection of RBC-Ecto purified from aged erythrocytes 
amplified systemic inflammation in endotoxemic mice. RBC-Ecto treated mice had elevated 
levels of pro-inflammatory cytokines in plasma,  peripheral blood leukopenia and lung leukocyte 
sequestration. These effects were C5aR dependent and could be reversed by inhibiting 
thrombin generation both in vitro and vivo. While PS liposomes were able to reproduce 
inflammatory effects of RBC-Ecto, systemic injection of hemoglobin contained in aged RBC-
Ecto did not amplify inflammation. This suggested that PS expressed on the surface RBC-Ecto 
amplifies systemic inflammation by thrombin dependent generation of C5a. There are, however, 
several aspects of both the model and mechanism of RBC-Ecto mediated inflammation that still 
need to be explained. 
 
RBC-Ecto amplified inflammation in LPS treated mice, but did not affect healthy mice. This went 
against our initial hypothesis where we expected inflammation with RBC-Ecto transfusion alone. 
There might be several reason why RBC-Ecto amplified inflammation in septic mice. Sepsis 
induces an acute phase response, which up-regulates critical components of the coagulation 
and complement cascade. With heightened sensitivity to exogenous insult, the mice were more 
likely to respond to RBC-Ecto transfusion. Furthermore, redistribution of leukocytes from the 
periphery to the lungs was more likely to occur in LPS treated mice which have activated 
leukocytes (C5aR expression) and lung endothelial cells (p-selectin expression). Lastly LPS 
treatment may have ensured longer half-life of transfused RBC-Ecto by down-regulating 
clearance mechanisms of the reticulo-endothelial system. It may have been necessary to 
saturate the clearance capacity for RBC-Ecto to allow pathology to unfold. In this respect 1x109 
RBC-Ecto, derived from 1ml of murine blood, needed to be transfused to achieve saturation. 
The amount of blood required to generate RBC-Ecto by ageing is likely an overestimation due to 
the fact that RBC-Ecto isolation from aged blood was very inefficient. RBC-Ecto yields from 
ionophore stimulated murine erythrocytes and human aged erythrocytes were substantially 
higher. 
In retrospect we neglected to measure C5a and thrombin generation in the C5aR-/- mice. The 
proof of heightened C5a and thrombin activation in C5aR-/- would formally confirm that RBC-
Ecto effects rely on the C5aR. 
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The motivation to analyze lung pathology came from a clinical observation in patients 
undergoing dialysis on cuprophan membranes (17, 18). These membranes had a tendency to 
activate complement (C5a) and patients undergoing dialysis frequently complained about 
shortness of breath. This was due to lung edema caused by systemic complement activation 
and transient leukocyte sequestration in the lung. Expecting C5a as the major culprit in the 
transfusion model we analyzed lung leukocyte sequestration and edema. The functional impact 
of RBC-Ecto transfusion on lung physiology could be further assessed by measuring blood 
gases and by body pletysmography.   Impaired microcirculation of various other organs, such as 
the kidneys, is reported in septic states and may have been compromised as well. 
 
Correlating clotting and inflammatory parameters to the amount of RBC-Ecto isolated from 
peripheral blood in transfused patients over time would have been a valuable addition to the 
project. Other conditions, such as hemolytic uremic syndrome or sickle cell crisis, could have 
been also included. 
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